epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
apitegromab
Apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
atacicept
Atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atoncy
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
avasopasem
Avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
Awiqli (insulin icodec-abae)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Multaq

dronedarone

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Black Box Warnings .

Risk of Death, Stroke, and Heart Failure Increased if Decompensated Heart Failure or Permanent AFib

contraindicated in patients with symptomatic heart failure and recent decompensation requiring hospitalization, NYHA Class IV heart failure, or permanent atrial fibrillation; risk of death doubled in patients with decompensated heart failure or NYHA Class IV heart failure; risk of death, stroke, and hospitalization for heart failure doubled in patients with permanent atrial fibrillation

Adult Dosing .

Dosage forms:  TAB: 400 mg

atrial fibrillation/flutter

[400 mg PO bid]
Info: for maintenance rhythm control in patients with paroxysmal or persistent atrial fibrillation history; give with meals

renal dosing

[see below]
renal impairment: no adjustment
HD/PD: not defined

hepatic dosing

[see below]
severe impairment: contraindicated

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@7dedd415
  • hypersensitivity to drug or ingredient
  • heart failure, NYHA Class IV
  • symptomatic CHF with recent decompensation requiring hospitalization
  • atrial fibrillation, permanent
  • AV block, 2nd-3rd degree (patients without pacemaker)
  • sick sinus syndrome (patients without pacemaker)
  • HR <50 bpm
  • QTc >500 msec
  • PR interval >280 msec
  • hypokalemia
  • hypomagnesemia
  • hepatic impairment, severe
  • hepatotoxicity, amiodarone-associated
  • pulmonary toxicity, amiodarone-associated
  • pregnancy
  • avoid: breastfeeding during tx and x5 days after D/C
  • caution: patients of childbearing potential
  • caution: elderly patients

Drug Interactions .

Overview

dronedarone

antiarrhythmic

Interaction Characteristics:
  • CYP3A4 substrate
  • CYP2D6 inhibitor, weak
  • CYP3A4 inhibitor, moderate
  • P-gp inhibitor, strong
  • bradycardia
  • cardiotoxic effects
  • delays atrioventricular conduction
  • prolongs QT interval (known)

Contraindicated

  • adagrasib
  • Multaq (dronedarone)
    +
    adagrasib
    1 interaction

    Contraindicated

    dronedarone + adagrasib

    contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • amiodarone
  • Multaq (dronedarone)
    +
    amiodarone
    1 interaction

    Contraindicated

    dronedarone + amiodarone

    contraindicated: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • anagrelide
  • Multaq (dronedarone)
    +
    anagrelide
    1 interaction

    Contraindicated

    dronedarone + anagrelide

    contraindicated: combo may incr. risk of cardiotoxicity, QT prolongation, cardiac arrhythmias (additive effects)

  • apalutamide
  • Multaq (dronedarone)
    +
    apalutamide
    1 interaction

    Contraindicated

    dronedarone + apalutamide

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. dronedarone levels, efficacy (additive effects; hepatic metabolism induced)

  • apomorphine
  • Multaq (dronedarone)
    +
    apomorphine
    1 interaction

    Contraindicated

    dronedarone + apomorphine

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • arsenic trioxide
  • Multaq (dronedarone)
    +
    arsenic trioxide
    1 interaction

    Contraindicated

    dronedarone + arsenic trioxide

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • artemether/lumefantrine
  • Multaq (dronedarone)
    +
    artemether/ lumefantrine
    1 interaction

    Contraindicated

    dronedarone + artemether/ lumefantrine

    contraindicated: combo may incr. artemether/lumefantrine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

  • asenapine
  • Multaq (dronedarone)
    +
    asenapine
    1 interaction

    Contraindicated

    dronedarone + asenapine

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • atazanavir
  • Multaq (dronedarone)
    +
    atazanavir
    1 interaction

    Contraindicated

    dronedarone + atazanavir

    contraindicated: combo may incr. dronedarone levels, risk of QT and PR interval prolongation, cardiac arrhythmias, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • azithromycin
  • Multaq (dronedarone)
    +
    azithromycin
    1 interaction

    Contraindicated

    dronedarone + azithromycin

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • bedaquiline
  • Multaq (dronedarone)
    +
    bedaquiline
    1 interaction

    Contraindicated

    dronedarone + bedaquiline

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • cabozantinib
  • Multaq (dronedarone)
    +
    cabozantinib
    1 interaction

    Contraindicated

    dronedarone + cabozantinib

    contraindicated: combo may incr. cabozantinib levels, risk of QT prolongation, cardiac arrhythmias, HTN, GI or other bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

  • ceritinib
  • Multaq (dronedarone)
    +
    ceritinib
    1 interaction

    Contraindicated

    dronedarone + ceritinib

    contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • chloramphenicol
  • Multaq (dronedarone)
    +
    chloramphenicol
    1 interaction

    Contraindicated

    dronedarone + chloramphenicol

    contraindicated: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • chloroquine
  • Multaq (dronedarone)
    +
    chloroquine
    1 interaction

    Contraindicated

    dronedarone + chloroquine

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • cisapride
  • Multaq (dronedarone)
    +
    cisapride
    1 interaction

    Contraindicated

    dronedarone + cisapride

    contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • citalopram
  • Multaq (dronedarone)
    +
    citalopram
    1 interaction

    Contraindicated

    dronedarone + citalopram

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • clarithromycin
  • Multaq (dronedarone)
    +
    clarithromycin
    1 interaction

    Contraindicated

    dronedarone + clarithromycin

    contraindicated: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • clofazimine
  • Multaq (dronedarone)
    +
    clofazimine
    1 interaction

    Contraindicated

    dronedarone + clofazimine

    contraindicated: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • cobicistat
  • Multaq (dronedarone)
    +
    cobicistat
    1 interaction

    Contraindicated

    dronedarone + cobicistat

    contraindicated: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • colchicine
  • Multaq (dronedarone)
    +
    colchicine
    1 interaction

    Contraindicated

    dronedarone + colchicine

    CV RISK REDUCTION: contraindicated; GOUT or FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, use alternative or decr. colchicine dose based on indication during and x14 days after dronedarone use as follows: GOUT PROPHYLAXIS: give colchicine 0.3 mg qod-qd; ACUTE GOUT TX: avoid combo if already receiving colchicine for gout prophylaxis; otherwise, give colchicine 0.6 mg x1 only; FMF: decr. max colchicine dose to 0.6 mg/day divided qd-bid: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • crizotinib
  • Multaq (dronedarone)
    +
    crizotinib
    1 interaction

    Contraindicated

    dronedarone + crizotinib

    contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, bradycardia, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • cyclosporine
  • Multaq (dronedarone)
    +
    cyclosporine
    1 interaction

    Contraindicated

    dronedarone + cyclosporine

    contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, serious infection, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • darunavir
  • Multaq (dronedarone)
    +
    darunavir
    1 interaction

    Contraindicated

    dronedarone + darunavir

    contraindicated: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • degarelix
  • Multaq (dronedarone)
    +
    degarelix
    1 interaction

    Contraindicated

    dronedarone + degarelix

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • desflurane
  • Multaq (dronedarone)
    +
    desflurane
    1 interaction

    Contraindicated

    dronedarone + desflurane

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • desipramine
  • Multaq (dronedarone)
    +
    desipramine
    1 interaction

    Contraindicated

    dronedarone + desipramine

    contraindicated: combo may incr. desipramine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • dexmedetomidine injection
  • Multaq (dronedarone)
    +
    dexmedetomidine injection
    1 interaction

    Contraindicated

    dronedarone + dexmedetomidine injection

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, bradycardia (additive effects)

  • disopyramide
  • Multaq (dronedarone)
    +
    disopyramide
    1 interaction

    Contraindicated

    dronedarone + disopyramide

    contraindicated: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • dofetilide
  • Multaq (dronedarone)
    +
    dofetilide
    1 interaction

    Contraindicated

    dronedarone + dofetilide

    contraindicated: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • domperidone
  • Multaq (dronedarone)
    +
    domperidone
    1 interaction

    Contraindicated

    dronedarone + domperidone

    contraindicated: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • donepezil
  • Multaq (dronedarone)
    +
    donepezil
    1 interaction

    Contraindicated

    dronedarone + donepezil

    contraindicated: combo may incr. risk of QT and PR interval prolongation, cardiac arrhythmias, AV block, bradycardia (additive effects)

  • dordaviprone
  • Multaq (dronedarone)
    +
    dordaviprone
    1 interaction

    Contraindicated

    dronedarone + dordaviprone

    contraindicated: combo may incr. dordaviprone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • droperidol
  • Multaq (dronedarone)
    +
    droperidol
    1 interaction

    Contraindicated

    dronedarone + droperidol

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • encorafenib
  • Multaq (dronedarone)
    +
    encorafenib
    1 interaction

    Contraindicated

    dronedarone + encorafenib

    contraindicated: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, other adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

  • ephedra
  • Multaq (dronedarone)
    +
    ephedra
    1 interaction

    Contraindicated

    dronedarone + ephedra

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • epirubicin
  • Multaq (dronedarone)
    +
    epirubicin
    1 interaction

    Contraindicated

    dronedarone + epirubicin

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

  • eribulin
  • Multaq (dronedarone)
    +
    eribulin
    1 interaction

    Contraindicated

    dronedarone + eribulin

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • erythromycin
  • Multaq (dronedarone)
    +
    erythromycin
    1 interaction

    Contraindicated

    dronedarone + erythromycin

    contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • fexinidazole
  • Multaq (dronedarone)
    +
    fexinidazole
    1 interaction

    Contraindicated

    dronedarone + fexinidazole

    contraindicated during and x7 days after fexinidazole tx; if possible, do not initiate fexinidazole until 5 half-lives after dronedarone D/C: combo may decr. dronedarone levels, efficacy; may decr. fexinidazole active metabolite levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; hepatic metabolism inhibited, decr. conversion to active metabolites; additive effects, bradycardia may incr. risk of QT prolongation)

  • flecainide
  • Multaq (dronedarone)
    +
    flecainide
    1 interaction

    Contraindicated

    dronedarone + flecainide

    contraindicated: combo may incr. flecainide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • flibanserin
  • Multaq (dronedarone)
    +
    flibanserin
    1 interaction

    Contraindicated

    dronedarone + flibanserin

    contraindicated w/in 14 days prior to, during, and x2 days after flibanserin tx: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (including syncope), other adverse effects (hepatic metabolism inhibited)

  • fluconazole
  • Multaq (dronedarone)
    +
    fluconazole
    1 interaction

    Contraindicated

    dronedarone + fluconazole

    contraindicated: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • fluorouracil
  • Multaq (dronedarone)
    +
    fluorouracil
    1 interaction

    Contraindicated

    dronedarone + fluorouracil

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

  • fosfomycin injection
  • Multaq (dronedarone)
    +
    fosfomycin injection
    1 interaction

    Contraindicated

    dronedarone + fosfomycin injection

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • gilteritinib
  • Multaq (dronedarone)
    +
    gilteritinib
    1 interaction

    Contraindicated

    dronedarone + gilteritinib

    contraindicated: combo may incr. gilteritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • glasdegib
  • Multaq (dronedarone)
    +
    glasdegib
    1 interaction

    Contraindicated

    dronedarone + glasdegib

    contraindicated: combo may incr. glasdegib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • goserelin
  • Multaq (dronedarone)
    +
    goserelin
    1 interaction

    Contraindicated

    dronedarone + goserelin

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • haloperidol
  • Multaq (dronedarone)
    +
    haloperidol
    1 interaction

    Contraindicated

    dronedarone + haloperidol

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • histrelin
  • Multaq (dronedarone)
    +
    histrelin
    1 interaction

    Contraindicated

    dronedarone + histrelin

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • hydroxychloroquine
  • Multaq (dronedarone)
    +
    hydroxychloroquine
    1 interaction

    Contraindicated

    dronedarone + hydroxychloroquine

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

  • hydroxyzine
  • Multaq (dronedarone)
    +
    hydroxyzine
    1 interaction

    Contraindicated

    dronedarone + hydroxyzine

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ibutilide
  • Multaq (dronedarone)
    +
    ibutilide
    1 interaction

    Contraindicated

    dronedarone + ibutilide

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • idelalisib
  • Multaq (dronedarone)
    +
    idelalisib
    1 interaction

    Contraindicated

    dronedarone + idelalisib

    contraindicated: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • inotuzumab ozogamicin
  • Multaq (dronedarone)
    +
    inotuzumab ozogamicin
    1 interaction

    Contraindicated

    dronedarone + inotuzumab ozogamicin

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • isoflurane
  • Multaq (dronedarone)
    +
    isoflurane
    1 interaction

    Contraindicated

    dronedarone + isoflurane

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • itraconazole
  • Multaq (dronedarone)
    +
    itraconazole
    1 interaction

    Contraindicated

    dronedarone + itraconazole

    contraindicated during and x2wk after itraconazole tx: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • ivosidenib
  • Multaq (dronedarone)
    +
    ivosidenib
    1 interaction

    Contraindicated

    dronedarone + ivosidenib

    contraindicated: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects; hepatic metabolism induced)

  • ketoconazole
  • Multaq (dronedarone)
    +
    ketoconazole
    1 interaction

    Contraindicated

    dronedarone + ketoconazole

    contraindicated during and up to 1wk after ketoconazole tx: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • lefamulin
  • Multaq (dronedarone)
    +
    lefamulin
    1 interaction

    Contraindicated

    dronedarone + lefamulin

    contraindicated: combo with oral lefamulin may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects; combo with IV lefamulin may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • leuprolide
  • Multaq (dronedarone)
    +
    leuprolide
    1 interaction

    Contraindicated

    dronedarone + leuprolide

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • levofloxacin
  • Multaq (dronedarone)
    +
    levofloxacin
    1 interaction

    Contraindicated

    dronedarone + levofloxacin

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • levoketoconazole
  • Multaq (dronedarone)
    +
    levoketoconazole
    1 interaction

    Contraindicated

    dronedarone + levoketoconazole

    contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • lofexidine
  • Multaq (dronedarone)
    +
    lofexidine
    1 interaction

    Contraindicated

    dronedarone + lofexidine

    contraindicated: combo may incr. risk of bradycardia, QT prolongation, cardiac arrhythmias (additive effects)

  • lomitapide
  • Multaq (dronedarone)
    +
    lomitapide
    1 interaction

    Contraindicated

    dronedarone + lomitapide

    contraindicated: combo may incr. lomitapide levels, risk of hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

  • lonafarnib
  • Multaq (dronedarone)
    +
    lonafarnib
    1 interaction

    Contraindicated

    dronedarone + lonafarnib

    contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • lopinavir/ritonavir
  • Multaq (dronedarone)
    +
    lopinavir/ ritonavir
    1 interaction

    Contraindicated

    dronedarone + lopinavir/ ritonavir

    contraindicated: combo may incr. or decr. dronedarone levels, incr. risk of QT and PR interval prolongation, cardiac arrhythmias, AV block, bradycardia, other adverse effects or decr. efficacy (hepatic metabolism altered, additive effects)

  • macimorelin
  • Multaq (dronedarone)
    +
    macimorelin
    1 interaction

    Contraindicated

    dronedarone + macimorelin

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • methadone
  • Multaq (dronedarone)
    +
    methadone
    1 interaction

    Contraindicated

    dronedarone + methadone

    contraindicated: combo may incr. methadone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • mifepristone
  • Multaq (dronedarone)
    +
    mifepristone
    1 interaction

    Contraindicated

    dronedarone + mifepristone

    contraindicated w/in 14 days of daily mifepristone use; caution advised if pregnancy termination use: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • mobocertinib
  • Multaq (dronedarone)
    +
    mobocertinib
    1 interaction

    Contraindicated

    dronedarone + mobocertinib

    contraindicated: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

  • moxifloxacin
  • Multaq (dronedarone)
    +
    moxifloxacin
    1 interaction

    Contraindicated

    dronedarone + moxifloxacin

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • nefazodone
  • Multaq (dronedarone)
    +
    nefazodone
    1 interaction

    Contraindicated

    dronedarone + nefazodone

    contraindicated: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • nelfinavir
  • Multaq (dronedarone)
    +
    nelfinavir
    1 interaction

    Contraindicated

    dronedarone + nelfinavir

    contraindicated: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • nilotinib
  • Multaq (dronedarone)
    +
    nilotinib
    1 interaction

    Contraindicated

    dronedarone + nilotinib

    contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • oliceridine
  • Multaq (dronedarone)
    +
    oliceridine
    1 interaction

    Contraindicated

    dronedarone + oliceridine

    contraindicated: combo may incr. oliceridine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ondansetron
  • Multaq (dronedarone)
    +
    ondansetron
    1 interaction

    Contraindicated

    dronedarone + ondansetron

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • osimertinib
  • Multaq (dronedarone)
    +
    osimertinib
    1 interaction

    Contraindicated

    dronedarone + osimertinib

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pacritinib
  • Multaq (dronedarone)
    +
    pacritinib
    1 interaction

    Contraindicated

    dronedarone + pacritinib

    contraindicated: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (including life-threatening), other adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

  • paliperidone
  • Multaq (dronedarone)
    +
    paliperidone
    1 interaction

    Contraindicated

    dronedarone + paliperidone

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • palonosetron
  • Multaq (dronedarone)
    +
    palonosetron
    1 interaction

    Contraindicated

    dronedarone + palonosetron

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pasireotide
  • Multaq (dronedarone)
    +
    pasireotide
    1 interaction

    Contraindicated

    dronedarone + pasireotide

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, bradycardia (additive effects)

  • pentamidine
  • Multaq (dronedarone)
    +
    pentamidine
    1 interaction

    Contraindicated

    dronedarone + pentamidine

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pimozide
  • Multaq (dronedarone)
    +
    pimozide
    1 interaction

    Contraindicated

    dronedarone + pimozide

    contraindicated: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • posaconazole
  • Multaq (dronedarone)
    +
    posaconazole
    1 interaction

    Contraindicated

    dronedarone + posaconazole

    contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • procainamide
  • Multaq (dronedarone)
    +
    procainamide
    1 interaction

    Contraindicated

    dronedarone + procainamide

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • propafenone
  • Multaq (dronedarone)
    +
    propafenone
    1 interaction

    Contraindicated

    dronedarone + propafenone

    contraindicated: combo may incr. propafenone levels, risk of QT prolongation, PR interval prolongation, AV block, bradycardia, cardiac arrhythmias, cardiotoxicity, hypotension, other adverse effects (hepatic metabolism inhibited, additive effects)

  • quinidine (antiarrhythmic)
  • Multaq (dronedarone)
    +
    quinidine (antiarrhythmic)
    1 interaction

    Contraindicated

    dronedarone + quinidine (antiarrhythmic)

    contraindicated: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, bradycardia, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • quinidine (CYP2D6 inhibitor)
  • Multaq (dronedarone)
    +
    quinidine (CYP2D6 inhibitor)
    1 interaction

    Contraindicated

    dronedarone + quinidine (CYP2D6 inhibitor)

    contraindicated: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • quinine
  • Multaq (dronedarone)
    +
    quinine
    1 interaction

    Contraindicated

    dronedarone + quinine

    contraindicated: combo may incr. quinine levels, risk of QT or PR interval prolongation, cardiac arrhythmias, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • quizartinib
  • Multaq (dronedarone)
    +
    quizartinib
    1 interaction

    Contraindicated

    dronedarone + quizartinib

    contraindicated: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • revumenib
  • Multaq (dronedarone)
    +
    revumenib
    1 interaction

    Contraindicated

    dronedarone + revumenib

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ribociclib
  • Multaq (dronedarone)
    +
    ribociclib
    1 interaction

    Contraindicated

    dronedarone + ribociclib

    contraindicated: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ritonavir
  • Multaq (dronedarone)
    +
    ritonavir
    1 interaction

    Contraindicated

    dronedarone + ritonavir

    contraindicated: combo may incr. dronedarone levels, risk of QT and PR interval prolongation, cardiac arrhythmias, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • romidepsin
  • Multaq (dronedarone)
    +
    romidepsin
    1 interaction

    Contraindicated

    dronedarone + romidepsin

    contraindicated: combo may incr. romidepsin levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (P-gp-mediated transport inhibited, additive effects)

  • rucaparib
  • Multaq (dronedarone)
    +
    rucaparib
    1 interaction

    Contraindicated

    dronedarone + rucaparib

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • selpercatinib
  • Multaq (dronedarone)
    +
    selpercatinib
    1 interaction

    Contraindicated

    dronedarone + selpercatinib

    contraindicated: combo may incr. selpercatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • sevoflurane
  • Multaq (dronedarone)
    +
    sevoflurane
    1 interaction

    Contraindicated

    dronedarone + sevoflurane

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • sotalol
  • Multaq (dronedarone)
    +
    sotalol
    1 interaction

    Contraindicated

    dronedarone + sotalol

    contraindicated: combo may incr. risk of QT and PR interval prolongation, cardiac arrhythmias, AV block, bradycardia (additive effects)

  • taletrectinib
  • Multaq (dronedarone)
    +
    taletrectinib
    1 interaction

    Contraindicated

    dronedarone + taletrectinib

    contraindicated: combo may incr. taletrectinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • telavancin
  • Multaq (dronedarone)
    +
    telavancin
    1 interaction

    Contraindicated

    dronedarone + telavancin

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • tetrabenazine
  • Multaq (dronedarone)
    +
    tetrabenazine
    1 interaction

    Contraindicated

    dronedarone + tetrabenazine

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • thioridazine
  • Multaq (dronedarone)
    +
    thioridazine
    1 interaction

    Contraindicated

    dronedarone + thioridazine

    contraindicated: combo may incr. thioridazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • tipranavir
  • Multaq (dronedarone)
    +
    tipranavir
    1 interaction

    Contraindicated

    dronedarone + tipranavir

    contraindicated: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • toremifene
  • Multaq (dronedarone)
    +
    toremifene
    1 interaction

    Contraindicated

    dronedarone + toremifene

    contraindicated: combo may incr. toremifene levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • tramadol
  • Multaq (dronedarone)
    +
    tramadol
    1 interaction

    Contraindicated

    dronedarone + tramadol

    contraindicated: combo may incr. tramadol, alter active metabolite levels, incr. risk of CNS and respiratory depression, psychomotor impairment, seizures, serotonin syndrome, QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism inhibited, may alter production of active metabolite; additive effects)

  • triclabendazole
  • Multaq (dronedarone)
    +
    triclabendazole
    1 interaction

    Contraindicated

    dronedarone + triclabendazole

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • trifluridine
  • Multaq (dronedarone)
    +
    trifluridine
    1 interaction

    Contraindicated

    dronedarone + trifluridine

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • triptorelin
  • Multaq (dronedarone)
    +
    triptorelin
    1 interaction

    Contraindicated

    dronedarone + triptorelin

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • tucatinib
  • Multaq (dronedarone)
    +
    tucatinib
    1 interaction

    Contraindicated

    dronedarone + tucatinib

    contraindicated: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • vandetanib
  • Multaq (dronedarone)
    +
    vandetanib
    1 interaction

    Contraindicated

    dronedarone + vandetanib

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

  • vemurafenib
  • Multaq (dronedarone)
    +
    vemurafenib
    1 interaction

    Contraindicated

    dronedarone + vemurafenib

    contraindicated: combo may incr. vemurafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

  • voriconazole
  • Multaq (dronedarone)
    +
    voriconazole
    1 interaction

    Contraindicated

    dronedarone + voriconazole

    contraindicated: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ziftomenib
  • Multaq (dronedarone)
    +
    ziftomenib
    1 interaction

    Contraindicated

    dronedarone + ziftomenib

    contraindicated: combo may incr. ziftomenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ziprasidone
  • Multaq (dronedarone)
    +
    ziprasidone
    1 interaction

    Contraindicated

    dronedarone + ziprasidone

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Avoid/Use Alternative

  • albuterol
  • Multaq (dronedarone)
    +
    albuterol
    1 interaction

    Avoid/Use Alternative

    dronedarone + albuterol

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • albuterol inhaled
  • Multaq (dronedarone)
    +
    albuterol inhaled
    1 interaction

    Avoid/Use Alternative

    dronedarone + albuterol inhaled

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • alfentanil
  • Multaq (dronedarone)
    +
    alfentanil
    1 interaction

    Avoid/Use Alternative

    dronedarone + alfentanil

    use alternative or monitor HR, respiratory rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and respiratory depression, psychomotor impairment, delayed recovery from anesthesia, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • alfuzosin
  • Multaq (dronedarone)
    +
    alfuzosin
    1 interaction

    Avoid/Use Alternative

    dronedarone + alfuzosin

    use alternative or monitor BP, ECG: combo may incr. alfuzosin levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

  • alprazolam
  • Multaq (dronedarone)
    +
    alprazolam
    1 interaction

    Avoid/Use Alternative

    dronedarone + alprazolam

    use alternative or monitor respiratory rate; consider decr. alprazolam dose: combo may incr. alprazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • amisulpride
  • Multaq (dronedarone)
    +
    amisulpride
    1 interaction

    Avoid/Use Alternative

    dronedarone + amisulpride

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • amitriptyline
  • Multaq (dronedarone)
    +
    amitriptyline
    1 interaction

    Avoid/Use Alternative

    dronedarone + amitriptyline

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • aprepitant
  • Multaq (dronedarone)
    +
    aprepitant
    1 interaction

    Avoid/Use Alternative

    dronedarone + aprepitant

    avoid combo w/ oral aprepitant; IV aprepitant use OK: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • arformoterol inhaled
  • Multaq (dronedarone)
    +
    arformoterol inhaled
    1 interaction

    Avoid/Use Alternative

    dronedarone + arformoterol inhaled

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • asciminib
  • Multaq (dronedarone)
    +
    asciminib
    1 interaction

    Avoid/Use Alternative

    dronedarone + asciminib

    use alternative or monitor cardiac fxn, incl. ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

  • avapritinib
  • Multaq (dronedarone)
    +
    avapritinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + avapritinib

    GIST: use alternative or monitor bleeding s/sx; decr. avapritinib start dose to 100 mg qd; ADVANCED SYSTEMIC MASTOCYTOSIS: use alternative or monitor bleeding s/sx; decr. avapritinib start dose to 50 mg qd; INDOLENT SYSTEMIC MASTOCYTOSIS: avoid combo: combo may incr. avapritinib levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

  • berotralstat
  • Multaq (dronedarone)
    +
    berotralstat
    1 interaction

    Avoid/Use Alternative

    dronedarone + berotralstat

    use alternative or monitor ECG: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • bosentan
  • Multaq (dronedarone)
    +
    bosentan
    1 interaction

    Avoid/Use Alternative

    dronedarone + bosentan

    avoid combo: combo may incr. bosentan levels, risk of adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

  • bosutinib
  • Multaq (dronedarone)
    +
    bosutinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + bosutinib

    avoid combo: combo may incr. bosutinib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • brigatinib
  • Multaq (dronedarone)
    +
    brigatinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + brigatinib

    use alternative or monitor BP, HR; decr. brigatinib dose by approx. 40% as follows: if taking 180 mg, decr. to 120 mg, if taking 120 mg, decr. to 90 mg; if taking 90 mg, decr. to 60 mg: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

  • buprenorphine
  • Multaq (dronedarone)
    +
    buprenorphine
    1 interaction

    Avoid/Use Alternative

    dronedarone + buprenorphine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • buspirone
  • Multaq (dronedarone)
    +
    buspirone
    1 interaction

    Avoid/Use Alternative

    dronedarone + buspirone

    consider alternative or restart buspirone dose at 2.5 mg bid: combo may incr. buspirone levels, risk of adverse effects (hepatic metabolism inhibited)

  • butalbital
  • Multaq (dronedarone)
    +
    butalbital
    1 interaction

    Avoid/Use Alternative

    dronedarone + butalbital

    avoid combo: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • carbamazepine
  • Multaq (dronedarone)
    +
    carbamazepine
    1 interaction

    Avoid/Use Alternative

    dronedarone + carbamazepine

    avoid combo: combo may decr. dronedarone levels, efficacy; may incr. carbamazepine levels, risk of PR interval prolongation, AV block, bradycardia, other adverse effects (hepatic metabolism induced; hepatic metabolism inhibited, additive effects)

  • cariprazine
  • Multaq (dronedarone)
    +
    cariprazine
    1 interaction

    Avoid/Use Alternative

    dronedarone + cariprazine

    IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING DRONEDARONE: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

  • cenobamate
  • Multaq (dronedarone)
    +
    cenobamate
    1 interaction

    Avoid/Use Alternative

    dronedarone + cenobamate

    avoid combo: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • chlorpromazine
  • Multaq (dronedarone)
    +
    chlorpromazine
    1 interaction

    Avoid/Use Alternative

    dronedarone + chlorpromazine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ciprofloxacin
  • Multaq (dronedarone)
    +
    ciprofloxacin
    1 interaction

    Avoid/Use Alternative

    dronedarone + ciprofloxacin

    avoid combo: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • clomipramine
  • Multaq (dronedarone)
    +
    clomipramine
    1 interaction

    Avoid/Use Alternative

    dronedarone + clomipramine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • clonidine
  • Multaq (dronedarone)
    +
    clonidine
    1 interaction

    Avoid/Use Alternative

    dronedarone + clonidine

    if ADHD use, avoid combo; otherwise, monitor HR: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • clozapine
  • Multaq (dronedarone)
    +
    clozapine
    1 interaction

    Avoid/Use Alternative

    dronedarone + clozapine

    use alternative or monitor ECG, BP, HR, electrolytes; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, severe bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • cobimetinib
  • Multaq (dronedarone)
    +
    cobimetinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + cobimetinib

    avoid combo or decr. cobimetinib dose to 20 mg/day and limit tx w/ dronedarone to 14 days: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • codeine
  • Multaq (dronedarone)
    +
    codeine
    1 interaction

    Avoid/Use Alternative

    dronedarone + codeine

    use alternative or monitor respiratory rate, withdrawal sx: combo may incr. codeine, alter metabolite morphine levels, incr. risk of CNS and respiratory depression, psychomotor impairment, other adverse effects or decr. efficacy (hepatic metabolism inhibited, may alter production of active metabolite morphine)

  • conivaptan
  • Multaq (dronedarone)
    +
    conivaptan
    1 interaction

    Avoid/Use Alternative

    dronedarone + conivaptan

    consider alternative or monitor ECG during and x7 days after conivaptan tx: combo may incr. levels of both drugs, risk of overly rapid serum sodium correction, neurologic sequelae, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • dabigatran
  • Multaq (dronedarone)
    +
    dabigatran
    1 interaction

    Avoid/Use Alternative

    dronedarone + dabigatran

    ATRIAL FIBRILLATION: decr. dabigatran dose to 75 mg BID if CrCl 30-50 mL/min; avoid combo if CrCl <30 mL/min; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; if dabigatran use for DVT/PE prophylaxis post-hip replacement and CrCl >50 mL/min, consider separating admin. at least 2h apart: combo may incr. dabigatran levels, risk of bleeding (including life-threatening), other adverse effects (P-gp-mediated transport inhibited)

  • dabrafenib
  • Multaq (dronedarone)
    +
    dabrafenib
    1 interaction

    Avoid/Use Alternative

    dronedarone + dabrafenib

    avoid combo: combo may decr. dronedarone levels, efficacy; may incr. risk of cardiotoxicity (hepatic metabolism induced; additive effects)

  • dasatinib
  • Multaq (dronedarone)
    +
    dasatinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + dasatinib

    use alternative or monitor ECG, electrolytes, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • defactinib
  • Multaq (dronedarone)
    +
    defactinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + defactinib

    avoid combo: combo may incr. defactinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • deutetrabenazine
  • Multaq (dronedarone)
    +
    deutetrabenazine
    1 interaction

    Avoid/Use Alternative

    dronedarone + deutetrabenazine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dexmedetomidine
  • Multaq (dronedarone)
    +
    dexmedetomidine
    1 interaction

    Avoid/Use Alternative

    dronedarone + dexmedetomidine

    avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, bradycardia (additive effects)

  • digoxin
  • Multaq (dronedarone)
    +
    digoxin
    1 interaction

    Avoid/Use Alternative

    dronedarone + digoxin

    use alternative or monitor digoxin levels, HR; decr. digoxin frequency or dose by 50%: combo may incr. digoxin levels, risk of PR interval prolongation, bradycardia, AV block, other adverse effects (P-gp-mediated transport inhibited, additive effects)

  • dihydrocodeine
  • Multaq (dronedarone)
    +
    dihydrocodeine
    1 interaction

    Avoid/Use Alternative

    dronedarone + dihydrocodeine

    use alternative or monitor respiratory rate, withdrawal sx; consider dihydrocodeine dose adjustment: combo may incr. dihydrocodeine levels, alter metabolite dihydromorphine levels, incr. risk of CNS and respiratory depression, psychomotor impairment, other adverse effects or decr. efficacy (hepatic metabolism inhibited, may alter production of active metabolite dihydromorphine)

  • dihydroergotamine
  • Multaq (dronedarone)
    +
    dihydroergotamine
    1 interaction

    Avoid/Use Alternative

    dronedarone + dihydroergotamine

    use alternative: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

  • doxorubicin
  • Multaq (dronedarone)
    +
    doxorubicin
    1 interaction

    Avoid/Use Alternative

    dronedarone + doxorubicin

    avoid combo: combo may incr. doxorubicin levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • efavirenz
  • Multaq (dronedarone)
    +
    efavirenz
    1 interaction

    Avoid/Use Alternative

    dronedarone + efavirenz

    avoid combo: combo may decr. dronedarone levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

  • elacestrant
  • Multaq (dronedarone)
    +
    elacestrant
    1 interaction

    Avoid/Use Alternative

    dronedarone + elacestrant

    avoid combo: combo may incr. elacestrant levels, risk of adverse effects (hepatic metabolism inhibited)

  • eliglustat
  • Multaq (dronedarone)
    +
    eliglustat
    1 interaction

    Avoid/Use Alternative

    dronedarone + eliglustat

    avoid combo: combo may incr. eliglustat levels, risk of PR or QT prolongation, bradycardia, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ensartinib
  • Multaq (dronedarone)
    +
    ensartinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + ensartinib

    avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (hepatic metabolism possibly inhibited, P-gp-mediated transport possibly inhibited, additive effects)

  • entrectinib
  • Multaq (dronedarone)
    +
    entrectinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + entrectinib

    avoid combo: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • enzalutamide
  • Multaq (dronedarone)
    +
    enzalutamide
    1 interaction

    Avoid/Use Alternative

    dronedarone + enzalutamide

    avoid combo: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • ergotamine
  • Multaq (dronedarone)
    +
    ergotamine
    1 interaction

    Avoid/Use Alternative

    dronedarone + ergotamine

    use alternative: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

  • escitalopram
  • Multaq (dronedarone)
    +
    escitalopram
    1 interaction

    Avoid/Use Alternative

    dronedarone + escitalopram

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • etrasimod
  • Multaq (dronedarone)
    +
    etrasimod
    1 interaction

    Avoid/Use Alternative

    dronedarone + etrasimod

    if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, use alternative or monitor HR, ECG, especially when starting or restarting etrasimod tx: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT and PR interval prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

  • etravirine
  • Multaq (dronedarone)
    +
    etravirine
    1 interaction

    Avoid/Use Alternative

    dronedarone + etravirine

    avoid combo: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • fentanyl
  • Multaq (dronedarone)
    +
    fentanyl
    1 interaction

    Avoid/Use Alternative

    dronedarone + fentanyl

    use alternative or monitor respiratory rate, HR; consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and respiratory depression, psychomotor impairment, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • fingolimod
  • Multaq (dronedarone)
    +
    fingolimod
    1 interaction

    Avoid/Use Alternative

    dronedarone + fingolimod

    use alternative or monitor HR, ECG overnight, esp. during fingolimod initiation/titration: combo may incr. risk of QT prolongation, PR interval prolongation, AV block, bradycardia, other cardiac arrhythmias (additive effects)

  • fluoxetine
  • Multaq (dronedarone)
    +
    fluoxetine
    1 interaction

    Avoid/Use Alternative

    dronedarone + fluoxetine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • formoterol inhaled
  • Multaq (dronedarone)
    +
    formoterol inhaled
    1 interaction

    Avoid/Use Alternative

    dronedarone + formoterol inhaled

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • fosaprepitant
  • Multaq (dronedarone)
    +
    fosaprepitant
    1 interaction

    Avoid/Use Alternative

    dronedarone + fosaprepitant

    avoid combo: combo may incr. aprepitant levels, risk of adverse effects (hepatic metabolism inhibited)

  • foscarnet
  • Multaq (dronedarone)
    +
    foscarnet
    1 interaction

    Avoid/Use Alternative

    dronedarone + foscarnet

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • fosphenytoin
  • Multaq (dronedarone)
    +
    fosphenytoin
    1 interaction

    Avoid/Use Alternative

    dronedarone + fosphenytoin

    avoid combo: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • fostemsavir
  • Multaq (dronedarone)
    +
    fostemsavir
    1 interaction

    Avoid/Use Alternative

    dronedarone + fostemsavir

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • gemtuzumab ozogamicin
  • Multaq (dronedarone)
    +
    gemtuzumab ozogamicin
    1 interaction

    Avoid/Use Alternative

    dronedarone + gemtuzumab ozogamicin

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • gepirone
  • Multaq (dronedarone)
    +
    gepirone
    1 interaction

    Avoid/Use Alternative

    dronedarone + gepirone

    use alternative or monitor ECG, electrolytes; decr. gepirone dose 50%: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • gepotidacin
  • Multaq (dronedarone)
    +
    gepotidacin
    1 interaction

    Avoid/Use Alternative

    dronedarone + gepotidacin

    use alternative or monitor ECG, electrolytes: combo may incr. gepotidacin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • givinostat
  • Multaq (dronedarone)
    +
    givinostat
    1 interaction

    Avoid/Use Alternative

    dronedarone + givinostat

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • granisetron
  • Multaq (dronedarone)
    +
    granisetron
    1 interaction

    Avoid/Use Alternative

    dronedarone + granisetron

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • grapefruit
  • Multaq (dronedarone)
    +
    grapefruit
    1 interaction

    Avoid/Use Alternative

    dronedarone + grapefruit

    avoid grapefruit juice: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (GI metabolism inhibited, additive effects)

  • hydrocodone
  • Multaq (dronedarone)
    +
    hydrocodone
    1 interaction

    Avoid/Use Alternative

    dronedarone + hydrocodone

    use alternative or monitor respiratory rate, ECG, electrolytes, especially if hydrocodone ER doses >160 mg/day; consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • idarubicin
  • Multaq (dronedarone)
    +
    idarubicin
    1 interaction

    Avoid/Use Alternative

    dronedarone + idarubicin

    use alternative at least 5 half-lives after dronedarone D/C; otherwise, monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

  • iloperidone
  • Multaq (dronedarone)
    +
    iloperidone
    1 interaction

    Avoid/Use Alternative

    dronedarone + iloperidone

    use alternative or monitor ECG, electrolytes: combo may incr. iloperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ivabradine
  • Multaq (dronedarone)
    +
    ivabradine
    1 interaction

    Avoid/Use Alternative

    dronedarone + ivabradine

    avoid combo: combo may incr. ivabradine levels, risk of PR interval prolongation, AV block, bradycardia, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ivacaftor
  • Multaq (dronedarone)
    +
    ivacaftor
    1 interaction

    Avoid/Use Alternative

    dronedarone + ivacaftor

    pts <6 mo: avoid combo; pts >6 mo decr. ivacaftor dose as follows: 6 mo-5 yo and 5-6.9 kg: give 25 mg qd; 6 mo-5 yo and 7-13.9 kg: give 50 mg qd; 6 mo-5 yo and >14 kg: give 75 mg qd; 6 yo and older: give 150 mg qd: combo may incr. ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

  • ixabepilone
  • Multaq (dronedarone)
    +
    ixabepilone
    1 interaction

    Avoid/Use Alternative

    dronedarone + ixabepilone

    consider alternatives or monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metabolism inhibited)

  • landiolol
  • Multaq (dronedarone)
    +
    landiolol
    1 interaction

    Avoid/Use Alternative

    dronedarone + landiolol

    avoid combo: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • lapatinib
  • Multaq (dronedarone)
    +
    lapatinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + lapatinib

    use alternative or monitor ECG; consider decr. lapatinib dose: combo may incr. lapatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • lemborexant
  • Multaq (dronedarone)
    +
    lemborexant
    1 interaction

    Avoid/Use Alternative

    dronedarone + lemborexant

    avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • lenacapavir
  • Multaq (dronedarone)
    +
    lenacapavir
    1 interaction

    Avoid/Use Alternative

    dronedarone + lenacapavir

    avoid combo if also combined w/ strong CYP3A4 and UGT1A1 inhibitors; otherwise, monitor ECG during and x9mo after lenacapavir tx: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • lenvatinib
  • Multaq (dronedarone)
    +
    lenvatinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + lenvatinib

    use alternative or monitor ECG, cardiac fxn: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

  • levalbuterol inhaled
  • Multaq (dronedarone)
    +
    levalbuterol inhaled
    1 interaction

    Avoid/Use Alternative

    dronedarone + levalbuterol inhaled

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • loperamide
  • Multaq (dronedarone)
    +
    loperamide
    1 interaction

    Avoid/Use Alternative

    dronedarone + loperamide

    use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. loperamide levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • lorlatinib
  • Multaq (dronedarone)
    +
    lorlatinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + lorlatinib

    avoid combo: combo may decr. dronedarone levels, efficacy; may incr. risk of PR interval prolongation, AV block, bradycardia (hepatic metabolism induced; additive effects)

  • lovastatin
  • Multaq (dronedarone)
    +
    lovastatin
    1 interaction

    Avoid/Use Alternative

    dronedarone + lovastatin

    use alternative or monitor CK, myopathy sx; adjust lovastatin max dose to 20 mg/day: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • lumacaftor/ivacaftor
  • Multaq (dronedarone)
    +
    lumacaftor/ ivacaftor
    1 interaction

    Avoid/Use Alternative

    dronedarone + lumacaftor/ ivacaftor

    avoid combo: combo may decr. dronedarone levels, efficacy; may incr. ivacaftor levels, risk of adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

  • lurasidone
  • Multaq (dronedarone)
    +
    lurasidone
    1 interaction

    Avoid/Use Alternative

    dronedarone + lurasidone

    use alternative or monitor ECG; decr. lurasidone start dose to 20 mg or decr. usual lurasidone dose 50%, max 80 mg/day: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • lurbinectedin
  • Multaq (dronedarone)
    +
    lurbinectedin
    1 interaction

    Avoid/Use Alternative

    dronedarone + lurbinectedin

    use alternative or monitor CBC; decr. lurbinectedin dose 50%: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • macitentan
  • Multaq (dronedarone)
    +
    macitentan
    1 interaction

    Avoid/Use Alternative

    dronedarone + macitentan

    if also combined w/ strong-mod CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. macitentan levels, risk of adverse effects (hepatic metabolism inhibited)

  • mavacamten
  • Multaq (dronedarone)
    +
    mavacamten
    1 interaction

    Avoid/Use Alternative

    dronedarone + mavacamten

    avoid combo: combo may incr. mavacamten levels, risk of cardiotoxicity (including heart failure), other adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

  • mavorixafor
  • Multaq (dronedarone)
    +
    mavorixafor
    1 interaction

    Avoid/Use Alternative

    dronedarone + mavorixafor

    use alternative or monitor ECG: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • mefloquine
  • Multaq (dronedarone)
    +
    mefloquine
    1 interaction

    Avoid/Use Alternative

    dronedarone + mefloquine

    use alternative or monitor ECG, HR: combo may incr. mefloquine levels, risk of QT and PR interval prolongation, cardiac arrhythmias, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • meperidine
  • Multaq (dronedarone)
    +
    meperidine
    1 interaction

    Avoid/Use Alternative

    dronedarone + meperidine

    use alternative or monitor respiratory rate, ECG; consider decr. meperidine dose: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • methylergonovine
  • Multaq (dronedarone)
    +
    methylergonovine
    1 interaction

    Avoid/Use Alternative

    dronedarone + methylergonovine

    avoid combo: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

  • metronidazole
  • Multaq (dronedarone)
    +
    metronidazole
    1 interaction

    Avoid/Use Alternative

    dronedarone + metronidazole

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • midazolam
  • Multaq (dronedarone)
    +
    midazolam
    1 interaction

    Avoid/Use Alternative

    dronedarone + midazolam

    avoid combo if midazolam nasal use; otherwise, monitor respiratory rate, consider decr. midazolam dose: combo may incr. midazolam and active metabolite levels, risk of profound CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • midostaurin
  • Multaq (dronedarone)
    +
    midostaurin
    1 interaction

    Avoid/Use Alternative

    dronedarone + midostaurin

    use alternative or monitor ECG, CBC: combo may incr. midostaurin levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

  • milsaperidone
  • Multaq (dronedarone)
    +
    milsaperidone
    1 interaction

    Avoid/Use Alternative

    dronedarone + milsaperidone

    use alternative or monitor ECG, electrolytes: combo may incr. milsaperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • mirtazapine
  • Multaq (dronedarone)
    +
    mirtazapine
    1 interaction

    Avoid/Use Alternative

    dronedarone + mirtazapine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • mitapivat
  • Multaq (dronedarone)
    +
    mitapivat
    1 interaction

    Avoid/Use Alternative

    dronedarone + mitapivat

    avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

  • mitotane
  • Multaq (dronedarone)
    +
    mitotane
    1 interaction

    Avoid/Use Alternative

    dronedarone + mitotane

    avoid combo: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • modafinil
  • Multaq (dronedarone)
    +
    modafinil
    1 interaction

    Avoid/Use Alternative

    dronedarone + modafinil

    avoid combo: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • nafcillin
  • Multaq (dronedarone)
    +
    nafcillin
    1 interaction

    Avoid/Use Alternative

    dronedarone + nafcillin

    avoid combo: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • naloxegol
  • Multaq (dronedarone)
    +
    naloxegol
    1 interaction

    Avoid/Use Alternative

    dronedarone + naloxegol

    avoid combo or decr. naloxegol dose to 12.5 mg/day: combo may incr. naloxegol levels, risk of adverse effects (hepatic metabolism inhibited)

  • neratinib
  • Multaq (dronedarone)
    +
    neratinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + neratinib

    avoid combo: combo may incr. neratinib levels, risk of adverse effects (hepatic metabolism inhibited, P-gp mediated transport inhibited)

  • netupitant
  • Multaq (dronedarone)
    +
    netupitant
    1 interaction

    Avoid/Use Alternative

    dronedarone + netupitant

    use alternative or monitor ECG, consider decr. dronedarone dose during and x1wk after (fos)netupitant tx: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • nirogacestat
  • Multaq (dronedarone)
    +
    nirogacestat
    1 interaction

    Avoid/Use Alternative

    dronedarone + nirogacestat

    avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, hypophosphatemia, other adverse effects (hepatic metabolism inhibited)

  • nisoldipine
  • Multaq (dronedarone)
    +
    nisoldipine
    1 interaction

    Avoid/Use Alternative

    dronedarone + nisoldipine

    consider alternative or monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

  • ofloxacin
  • Multaq (dronedarone)
    +
    ofloxacin
    1 interaction

    Avoid/Use Alternative

    dronedarone + ofloxacin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • olaparib
  • Multaq (dronedarone)
    +
    olaparib
    1 interaction

    Avoid/Use Alternative

    dronedarone + olaparib

    use alternative or monitor CBC; decr. olaparib dose to 150 mg bid: combo may incr. olaparib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • olodaterol inhaled
  • Multaq (dronedarone)
    +
    olodaterol inhaled
    1 interaction

    Avoid/Use Alternative

    dronedarone + olodaterol inhaled

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • omaveloxolone
  • Multaq (dronedarone)
    +
    omaveloxolone
    1 interaction

    Avoid/Use Alternative

    dronedarone + omaveloxolone

    use alternative or decr. omaveloxolone dose to 100 mg/day: combo may incr. omaveloxolone levels, risk of adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

  • osilodrostat
  • Multaq (dronedarone)
    +
    osilodrostat
    1 interaction

    Avoid/Use Alternative

    dronedarone + osilodrostat

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • oxaliplatin
  • Multaq (dronedarone)
    +
    oxaliplatin
    1 interaction

    Avoid/Use Alternative

    dronedarone + oxaliplatin

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • oxycodone
  • Multaq (dronedarone)
    +
    oxycodone
    1 interaction

    Avoid/Use Alternative

    dronedarone + oxycodone

    use alternative or monitor respiratory rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • ozanimod
  • Multaq (dronedarone)
    +
    ozanimod
    1 interaction

    Avoid/Use Alternative

    dronedarone + ozanimod

    use alternative or monitor HR, ECG, especially when starting or restarting ozanimod tx: combo may incr. risk of QT prolongation, PR interval prolongation, AV block, bradycardia, other cardiac arrhythmias (additive effects)

  • palovarotene
  • Multaq (dronedarone)
    +
    palovarotene
    1 interaction

    Avoid/Use Alternative

    dronedarone + palovarotene

    use alternative or decr. palovarotene dose as follows: wt 10-19.9 kg maint. dose 1 mg daily, flare dose 5 mg daily wk 1-4, then 2.5 mg daily wk 5-12; wt 20-39.9 kg maint. dose 1.5 mg daily, flare dose 6 mg daily wk 1-4, then 3 mg daily wk 5-12; wt 40-59.9 kg maint. dose 2 mg daily, flare dose 7.5 mg daily wk 1-4, then 4 mg daily wk 5-12; wt 60 kg and greater or 14 yo and older maint. dose 2.5 mg daily, flare dose 10 mg daily wk 1-4, then 5 mg daily wk 5-12: combo may incr. palovarotene levels, risk of adverse effects (hepatic metabolism inhibited)

  • pazopanib
  • Multaq (dronedarone)
    +
    pazopanib
    1 interaction

    Avoid/Use Alternative

    dronedarone + pazopanib

    avoid combo: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • pemigatinib
  • Multaq (dronedarone)
    +
    pemigatinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + pemigatinib

    use alternative or monitor phosphate and decr. pemigatinib dose as follows: if on pemigatinib 13.5 mg qd, decr. to 9 mg qd; if on pemigatinib 9 mg qd, decr. to 4.5 mg qd: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

  • pentobarbital
  • Multaq (dronedarone)
    +
    pentobarbital
    1 interaction

    Avoid/Use Alternative

    dronedarone + pentobarbital

    avoid combo: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • pexidartinib
  • Multaq (dronedarone)
    +
    pexidartinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + pexidartinib

    avoid combo: combo may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

  • phenobarbital
  • Multaq (dronedarone)
    +
    phenobarbital
    1 interaction

    Avoid/Use Alternative

    dronedarone + phenobarbital

    avoid combo: combo may decr. dronedarone levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metabolism induced; additive effects)

  • phenytoin
  • Multaq (dronedarone)
    +
    phenytoin
    1 interaction

    Avoid/Use Alternative

    dronedarone + phenytoin

    avoid combo: combo may decr. dronedarone levels, efficacy; may incr. risk of bradycardia (hepatic metabolism induced; additive effects)

  • pimavanserin
  • Multaq (dronedarone)
    +
    pimavanserin
    1 interaction

    Avoid/Use Alternative

    dronedarone + pimavanserin

    avoid combo: combo may incr. pimavanserin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • pitolisant
  • Multaq (dronedarone)
    +
    pitolisant
    1 interaction

    Avoid/Use Alternative

    dronedarone + pitolisant

    avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ponesimod
  • Multaq (dronedarone)
    +
    ponesimod
    1 interaction

    Avoid/Use Alternative

    dronedarone + ponesimod

    use alternative or monitor HR, ECG, especially when starting or restarting ponesimod tx: combo may incr. risk of QT prolongation, PR interval prolongation, AV block, bradycardia, other cardiac arrhythmias (additive effects)

  • pralsetinib
  • Multaq (dronedarone)
    +
    pralsetinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + pralsetinib

    use alternative or monitor ECG, consider monitoring electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • primaquine
  • Multaq (dronedarone)
    +
    primaquine
    1 interaction

    Avoid/Use Alternative

    dronedarone + primaquine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • primidone
  • Multaq (dronedarone)
    +
    primidone
    1 interaction

    Avoid/Use Alternative

    dronedarone + primidone

    avoid combo: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • promethazine
  • Multaq (dronedarone)
    +
    promethazine
    1 interaction

    Avoid/Use Alternative

    dronedarone + promethazine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • quetiapine
  • Multaq (dronedarone)
    +
    quetiapine
    1 interaction

    Avoid/Use Alternative

    dronedarone + quetiapine

    avoid combo: combo may incr. quetiapine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ranolazine
  • Multaq (dronedarone)
    +
    ranolazine
    1 interaction

    Avoid/Use Alternative

    dronedarone + ranolazine

    use alternative or monitor ECG; adjust ranolazine max dose to 1000 mg/day: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • relugolix
  • Multaq (dronedarone)
    +
    relugolix
    1 interaction

    Avoid/Use Alternative

    dronedarone + relugolix

    PROSTATE CANCER: may hold relugolix if dronedarone tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before dronedarone; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before dronedarone: combo may incr. relugolix levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (gut P-gp-mediated transport inhibited; additive effects, androgen deprivation may prolong QT)

  • remibrutinib
  • Multaq (dronedarone)
    +
    remibrutinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + remibrutinib

    avoid combo: combo may incr. remibrutinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • repotrectinib
  • Multaq (dronedarone)
    +
    repotrectinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + repotrectinib

    avoid combo; D/C dronedarone 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited, P-gp-mediated transport inhibited; hepatic metabolism induced)

  • rifabutin
  • Multaq (dronedarone)
    +
    rifabutin
    1 interaction

    Avoid/Use Alternative

    dronedarone + rifabutin

    avoid combo: combo may incr. rifabutin levels, risk of myelosuppression, uveitis, other adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

  • rifampin
  • Multaq (dronedarone)
    +
    rifampin
    1 interaction

    Avoid/Use Alternative

    dronedarone + rifampin

    avoid combo: combo may decr. dronedarone levels, efficacy; may incr. rifampin levels, risk of adverse effects (hepatic metabolism induced; P-gp-mediated transport inhibited)

  • rifapentine
  • Multaq (dronedarone)
    +
    rifapentine
    1 interaction

    Avoid/Use Alternative

    dronedarone + rifapentine

    avoid combo: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • rilpivirine
  • Multaq (dronedarone)
    +
    rilpivirine
    1 interaction

    Avoid/Use Alternative

    dronedarone + rilpivirine

    use alternative or monitor ECG; risk may be lower w/ IM rilpivirine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • rilzabrutinib
  • Multaq (dronedarone)
    +
    rilzabrutinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + rilzabrutinib

    avoid combo if dronedarone use greater than 7 days; use alternative or hold rilzabrutinib if dronedarone use less than 7 days: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • rivaroxaban
  • Multaq (dronedarone)
    +
    rivaroxaban
    1 interaction

    Avoid/Use Alternative

    dronedarone + rivaroxaban

    use alternative if CrCl <80; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • sacituzumab govitecan
  • Multaq (dronedarone)
    +
    sacituzumab govitecan
    1 interaction

    Avoid/Use Alternative

    dronedarone + sacituzumab govitecan

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • sebetralstat
  • Multaq (dronedarone)
    +
    sebetralstat
    1 interaction

    Avoid/Use Alternative

    dronedarone + sebetralstat

    use alternative or monitor ECG; decr. sebetralstat dose to 300 mg, may give second 300 mg dose at least 3h after first dose if needed: combo may incr. sebetralstat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • selumetinib
  • Multaq (dronedarone)
    +
    selumetinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + selumetinib

    use alternative or monitor cardiac fxn (incl. LVEF), CK, myopathy sx; decr. selumetinib dose as follows: if on selumetinib 25 mg/m^2 bid, decr. to 20 mg/m^2 bid; if on selumetinib 20 mg/m^2 bid, decr. to 15 mg/m^2 bid; see selumetinib pkg insert for specific dose adjustments: combo may incr. selumetinib levels, risk of cardiotoxicity, myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, additive effects)

  • sertraline
  • Multaq (dronedarone)
    +
    sertraline
    1 interaction

    Avoid/Use Alternative

    dronedarone + sertraline

    use alternative or monitor ECG: combo may incr. sertraline levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • silodosin
  • Multaq (dronedarone)
    +
    silodosin
    1 interaction

    Avoid/Use Alternative

    dronedarone + silodosin

    avoid combo: combo may incr. silodosin levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • simvastatin
  • Multaq (dronedarone)
    +
    simvastatin
    1 interaction

    Avoid/Use Alternative

    dronedarone + simvastatin

    use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 10 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • siponimod
  • Multaq (dronedarone)
    +
    siponimod
    1 interaction

    Avoid/Use Alternative

    dronedarone + siponimod

    use alternative or monitor HR, ECG, especially when starting or restarting siponimod tx; if also combined w/ strong CYP2C9 inhibitor, avoid combo: combo may incr. siponimod levels, risk of PR interval prolongation, AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

  • sirolimus
  • Multaq (dronedarone)
    +
    sirolimus
    1 interaction

    Avoid/Use Alternative

    dronedarone + sirolimus

    use alternative or monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • sirolimus albumin-bound
  • Multaq (dronedarone)
    +
    sirolimus albumin-bound
    1 interaction

    Avoid/Use Alternative

    dronedarone + sirolimus albumin-bound

    avoid combo: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • solifenacin
  • Multaq (dronedarone)
    +
    solifenacin
    1 interaction

    Avoid/Use Alternative

    dronedarone + solifenacin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • sonidegib
  • Multaq (dronedarone)
    +
    sonidegib
    1 interaction

    Avoid/Use Alternative

    dronedarone + sonidegib

    avoid combo or monitor closely: combo may incr. sonidegib levels, risk of adverse effects (hepatic metabolism inhibited)

  • sorafenib
  • Multaq (dronedarone)
    +
    sorafenib
    1 interaction

    Avoid/Use Alternative

    dronedarone + sorafenib

    use alternative or monitor ECG, electrolytes, cardiac fxn: combo may incr. risk of QT prolongation, cardiac arrhythmias, cardiotoxicity (additive effects)

  • sotorasib
  • Multaq (dronedarone)
    +
    sotorasib
    1 interaction

    Avoid/Use Alternative

    dronedarone + sotorasib

    avoid combo: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • St. John's wort
  • Multaq (dronedarone)
    +
    St. John's wort
    1 interaction

    Avoid/Use Alternative

    dronedarone + St. John's wort

    avoid combo: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • sufentanil
  • Multaq (dronedarone)
    +
    sufentanil
    1 interaction

    Avoid/Use Alternative

    dronedarone + sufentanil

    consider alternative or monitor respiratory rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • sunitinib
  • Multaq (dronedarone)
    +
    sunitinib
    1 interaction

    Avoid/Use Alternative

    dronedarone + sunitinib

    use alternative or monitor ECG, electrolytes, cardiac fxn; consider monitoring LVEF: combo may incr. sunitinib levels, risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • tacrolimus
  • Multaq (dronedarone)
    +
    tacrolimus
    1 interaction

    Avoid/Use Alternative

    dronedarone + tacrolimus

    use alternative or monitor tacrolimus levels, ECG, electrolytes, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • tazemetostat
  • Multaq (dronedarone)
    +
    tazemetostat
    1 interaction

    Avoid/Use Alternative

    dronedarone + tazemetostat

    use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

  • terbutaline
  • Multaq (dronedarone)
    +
    terbutaline
    1 interaction

    Avoid/Use Alternative

    dronedarone + terbutaline

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • tolterodine
  • Multaq (dronedarone)
    +
    tolterodine
    1 interaction

    Avoid/Use Alternative

    dronedarone + tolterodine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • tolvaptan
  • Multaq (dronedarone)
    +
    tolvaptan
    1 interaction

    Avoid/Use Alternative

    dronedarone + tolvaptan

    HYPONATREMIA USE: avoid combo; AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DZ USE: decr. tolvaptan total daily dose by 50% as follows: if taking 60 mg/day, decr. to 15 mg qam and 15 mg qpm; if taking 90 mg/day, decr. to 30 mg qam and 15 mg qpm; if taking 120 mg/day, decr. to 45 mg qam and 15 mg qpm: combo may incr. tolvaptan levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • topotecan
  • Multaq (dronedarone)
    +
    topotecan
    1 interaction

    Avoid/Use Alternative

    dronedarone + topotecan

    avoid combo w/ oral topotecan: combo may incr. topotecan levels, risk of serious infection, myelosuppression, other adverse effects (gut P-gp-mediated transport inhibited)

  • trazodone
  • Multaq (dronedarone)
    +
    trazodone
    1 interaction

    Avoid/Use Alternative

    dronedarone + trazodone

    use alternative or monitor ECG, BP: combo may incr. trazodone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited, additive effects)

  • valbenazine
  • Multaq (dronedarone)
    +
    valbenazine
    1 interaction

    Avoid/Use Alternative

    dronedarone + valbenazine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • vardenafil
  • Multaq (dronedarone)
    +
    vardenafil
    1 interaction

    Avoid/Use Alternative

    dronedarone + vardenafil

    use alternative or monitor ECG; max vardenafil dose 5 mg/24h; avoid combo w/ ODT form: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metabolism inhibited, additive effects)

  • venetoclax
  • Multaq (dronedarone)
    +
    venetoclax
    1 interaction

    Avoid/Use Alternative

    dronedarone + venetoclax

    monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • venlafaxine
  • Multaq (dronedarone)
    +
    venlafaxine
    1 interaction

    Avoid/Use Alternative

    dronedarone + venlafaxine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • vilanterol inhaled
  • Multaq (dronedarone)
    +
    vilanterol inhaled
    1 interaction

    Avoid/Use Alternative

    dronedarone + vilanterol inhaled

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • voclosporin
  • Multaq (dronedarone)
    +
    voclosporin
    1 interaction

    Avoid/Use Alternative

    dronedarone + voclosporin

    use alternative or monitor ECG, electrolytes, renal fxn; decr. voclosporin morning dose to 15.8 mg and evening dose to 7.9 mg: combo may incr. voclosporin levels, risk of QT prolongation, cardiac arrhythmias, serious infection, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

Monitor/Modify Tx

  • abemaciclib
  • Multaq (dronedarone)
    +
    abemaciclib
    1 interaction

    Monitor/Modify Tx

    dronedarone + abemaciclib

    consider decr. abemaciclib 200 mg bid dose to 150 mg bid, abemaciclib 150 mg bid dose to 100 mg bid, abemaciclib 100 mg bid dose to 50 mg bid; monitor CBC: combo may incr. abemaciclib levels, risk of serious infection, myelosuppression, thrombosis risk, other adverse effects (hepatic metabolism inhibited)

  • acalabrutinib
  • Multaq (dronedarone)
    +
    acalabrutinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + acalabrutinib

    decr. acalabrutinib dose to 100 mg qd; monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • acebutolol
  • Multaq (dronedarone)
    +
    acebutolol
    1 interaction

    Monitor/Modify Tx

    dronedarone + acebutolol

    start w/ low acebutolol dose, monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • adalimumab
  • Multaq (dronedarone)
    +
    adalimumab
    1 interaction

    Monitor/Modify Tx

    dronedarone + adalimumab

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • adenosine
  • Multaq (dronedarone)
    +
    adenosine
    1 interaction

    Monitor/Modify Tx

    dronedarone + adenosine

    monitor HR: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • ado-trastuzumab emtansine
  • Multaq (dronedarone)
    +
    ado-trastuzumab emtansine
    1 interaction

    Monitor/Modify Tx

    dronedarone + ado-trastuzumab emtansine

    monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

  • afatinib
  • Multaq (dronedarone)
    +
    afatinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + afatinib

    decr. afatinib dose by 10 mg/day if not tolerated: combo may incr. afatinib levels, risk of adverse effects (P-gp-mediated transport inhibited)

  • aficamten
  • Multaq (dronedarone)
    +
    aficamten
    1 interaction

    Monitor/Modify Tx

    dronedarone + aficamten

    monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

  • aldesleukin
  • Multaq (dronedarone)
    +
    aldesleukin
    1 interaction

    Monitor/Modify Tx

    dronedarone + aldesleukin

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • alectinib
  • Multaq (dronedarone)
    +
    alectinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + alectinib

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • amlodipine
  • Multaq (dronedarone)
    +
    amlodipine
    1 interaction

    Monitor/Modify Tx

    dronedarone + amlodipine

    monitor ECG, BP, HR; decr. (lev)amlodipine start dose: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, bradycardia, AV block, other adverse effects (hepatic metabolism inhibited)

  • apixaban
  • Multaq (dronedarone)
    +
    apixaban
    1 interaction

    Monitor/Modify Tx

    dronedarone + apixaban

    monitor bleeding s/sx: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • apraclonidine ophthalmic
  • Multaq (dronedarone)
    +
    apraclonidine ophthalmic
    1 interaction

    Monitor/Modify Tx

    dronedarone + apraclonidine ophthalmic

    monitor HR if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of bradycardia (additive effects)

  • aripiprazole oral
  • Multaq (dronedarone)
    +
    aripiprazole oral
    1 interaction

    Monitor/Modify Tx

    dronedarone + aripiprazole oral

    consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • articaine
  • Multaq (dronedarone)
    +
    articaine
    1 interaction

    Monitor/Modify Tx

    dronedarone + articaine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • atenolol
  • Multaq (dronedarone)
    +
    atenolol
    1 interaction

    Monitor/Modify Tx

    dronedarone + atenolol

    start w/ low atenolol dose, monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • atorvastatin
  • Multaq (dronedarone)
    +
    atorvastatin
    1 interaction

    Monitor/Modify Tx

    dronedarone + atorvastatin

    monitor CK, myopathy sx: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • avacopan
  • Multaq (dronedarone)
    +
    avacopan
    1 interaction

    Monitor/Modify Tx

    dronedarone + avacopan

    monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • avanafil
  • Multaq (dronedarone)
    +
    avanafil
    1 interaction

    Monitor/Modify Tx

    dronedarone + avanafil

    monitor BP; adjust max avanafil dose to 50 mg/24h: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

  • avatrombopag
  • Multaq (dronedarone)
    +
    avatrombopag
    1 interaction

    Monitor/Modify Tx

    dronedarone + avatrombopag

    CHRONIC IMMUNE THROMBOCYTOPENIA: monitor platelets, thrombosis s/sx; if avatrombopag tablet also combined w/ a moderate or strong CYP2C9 inhibitor, decr. start dose to 20 mg 3x/wk; if avatrombopag sprinkle also combined w/ a moderate or strong CYP2C9 inhibitor, decr. start dose to 10 mg 3x/wk; CHRONIC LIVER DZ: monitor platelets, thrombosis s/sx: combo may incr. avatrombopag levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • avelumab
  • Multaq (dronedarone)
    +
    avelumab
    1 interaction

    Monitor/Modify Tx

    dronedarone + avelumab

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • axitinib
  • Multaq (dronedarone)
    +
    axitinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + axitinib

    monitor cardiac fxn; consider decr. axitinib dose: combo may incr. axitinib levels, risk of cardiotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • betaxolol
  • Multaq (dronedarone)
    +
    betaxolol
    1 interaction

    Monitor/Modify Tx

    dronedarone + betaxolol

    start w/ low betaxolol dose, monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • betaxolol ophthalmic
  • Multaq (dronedarone)
    +
    betaxolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    dronedarone + betaxolol ophthalmic

    monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • bevacizumab
  • Multaq (dronedarone)
    +
    bevacizumab
    1 interaction

    Monitor/Modify Tx

    dronedarone + bevacizumab

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • bezlotoxumab
  • Multaq (dronedarone)
    +
    bezlotoxumab
    1 interaction

    Monitor/Modify Tx

    dronedarone + bezlotoxumab

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • binimetinib
  • Multaq (dronedarone)
    +
    binimetinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + binimetinib

    monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

  • bisoprolol
  • Multaq (dronedarone)
    +
    bisoprolol
    1 interaction

    Monitor/Modify Tx

    dronedarone + bisoprolol

    start w/ low bisoprolol dose, monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • bortezomib
  • Multaq (dronedarone)
    +
    bortezomib
    1 interaction

    Monitor/Modify Tx

    dronedarone + bortezomib

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • brexpiprazole
  • Multaq (dronedarone)
    +
    brexpiprazole
    1 interaction

    Monitor/Modify Tx

    dronedarone + brexpiprazole

    if CYP2D6 poor metabolizer or if also combined w/ moderate or strong CYP2D6 inhibitor, decr. brexpiprazole dose 75%: combo may incr. brexpiprazole levels, risk of adverse effects (hepatic metabolism inhibited)

  • bromocriptine
  • Multaq (dronedarone)
    +
    bromocriptine
    1 interaction

    Monitor/Modify Tx

    dronedarone + bromocriptine

    limit bromocriptine max dose to 1.6 mg/day if diabetes tx; otherwise, caution advised: combo may incr. bromocriptine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

  • budesonide
  • Multaq (dronedarone)
    +
    budesonide
    1 interaction

    Monitor/Modify Tx

    dronedarone + budesonide

    monitor hypercorticism s/sx: combo may incr. budesonide levels, risk of systemic corticosteroid effects, including Cushing syndrome, adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • bupivacaine
  • Multaq (dronedarone)
    +
    bupivacaine
    1 interaction

    Monitor/Modify Tx

    dronedarone + bupivacaine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • bupivacaine liposomal
  • Multaq (dronedarone)
    +
    bupivacaine liposomal
    1 interaction

    Monitor/Modify Tx

    dronedarone + bupivacaine liposomal

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • butorphanol
  • Multaq (dronedarone)
    +
    butorphanol
    1 interaction

    Monitor/Modify Tx

    dronedarone + butorphanol

    monitor respiratory rate, consider decr. butorphanol dose: combo may incr. butorphanol levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • capecitabine
  • Multaq (dronedarone)
    +
    capecitabine
    1 interaction

    Monitor/Modify Tx

    dronedarone + capecitabine

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • capivasertib
  • Multaq (dronedarone)
    +
    capivasertib
    1 interaction

    Monitor/Modify Tx

    dronedarone + capivasertib

    monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

  • carfilzomib
  • Multaq (dronedarone)
    +
    carfilzomib
    1 interaction

    Monitor/Modify Tx

    dronedarone + carfilzomib

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • carteolol ophthalmic
  • Multaq (dronedarone)
    +
    carteolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    dronedarone + carteolol ophthalmic

    monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • carvedilol
  • Multaq (dronedarone)
    +
    carvedilol
    1 interaction

    Monitor/Modify Tx

    dronedarone + carvedilol

    start w/ low carvedilol dose; monitor BP, HR, ECG: combo may incr. carvedilol levels, risk of hypotension, PR interval prolongation, AV block, bradycardia, other adverse effects (P-gp-mediated transport inhibited, additive effects)

  • certolizumab pegol
  • Multaq (dronedarone)
    +
    certolizumab pegol
    1 interaction

    Monitor/Modify Tx

    dronedarone + certolizumab pegol

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • chloroprocaine
  • Multaq (dronedarone)
    +
    chloroprocaine
    1 interaction

    Monitor/Modify Tx

    dronedarone + chloroprocaine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • cilostazol
  • Multaq (dronedarone)
    +
    cilostazol
    1 interaction

    Monitor/Modify Tx

    dronedarone + cilostazol

    decr. cilostazol dose to 50 mg bid: combo may incr. cilostazol levels, risk of adverse effects (hepatic metabolism inhibited)

  • clonazepam
  • Multaq (dronedarone)
    +
    clonazepam
    1 interaction

    Monitor/Modify Tx

    dronedarone + clonazepam

    monitor respiratory rate: combo may incr. clonazepam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • copanlisib
  • Multaq (dronedarone)
    +
    copanlisib
    1 interaction

    Monitor/Modify Tx

    dronedarone + copanlisib

    monitor CBC: combo may incr. copanlisib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • cyclophosphamide
  • Multaq (dronedarone)
    +
    cyclophosphamide
    1 interaction

    Monitor/Modify Tx

    dronedarone + cyclophosphamide

    monitor cardiac fxn: combo may decr. cyclophosphamide active metabolite levels, efficacy; may incr. risk of cardiotoxicity (hepatic metabolism possibly inhibited, decr. conversion to active metabolite; additive effects)

  • danazol
  • Multaq (dronedarone)
    +
    danazol
    1 interaction

    Monitor/Modify Tx

    dronedarone + danazol

    monitor ECG: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • daridorexant
  • Multaq (dronedarone)
    +
    daridorexant
    1 interaction

    Monitor/Modify Tx

    dronedarone + daridorexant

    adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • daunorubicin
  • Multaq (dronedarone)
    +
    daunorubicin
    1 interaction

    Monitor/Modify Tx

    dronedarone + daunorubicin

    monitor CBC, cardiac fxn, incl. LVEF: combo may incr. daunorubicin levels, risk of cardiotoxicity, serious infection, myelosuppression, other adverse effects (P-gp-mediated transport inhibited, additive effects)

  • deflazacort
  • Multaq (dronedarone)
    +
    deflazacort
    1 interaction

    Monitor/Modify Tx

    dronedarone + deflazacort

    decr. deflazacort to 1/3 usual dose: combo may incr. deflazacort active metabolite levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • diltiazem
  • Multaq (dronedarone)
    +
    diltiazem
    1 interaction

    Monitor/Modify Tx

    dronedarone + diltiazem

    start w/ low diltiazem dose; monitor BP, HR, ECG: combo may incr. levels of both drugs, risk of QT and PR interval prolongation, cardiac arrhythmias, hypotension, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • docetaxel
  • Multaq (dronedarone)
    +
    docetaxel
    1 interaction

    Monitor/Modify Tx

    dronedarone + docetaxel

    monitor CBC; consider decr. docetaxel dose: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • dulaglutide
  • Multaq (dronedarone)
    +
    dulaglutide
    1 interaction

    Monitor/Modify Tx

    dronedarone + dulaglutide

    monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • duvelisib
  • Multaq (dronedarone)
    +
    duvelisib
    1 interaction

    Monitor/Modify Tx

    dronedarone + duvelisib

    monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, arrhythmia, other adverse effects (hepatic metabolism inhibited)

  • edoxaban
  • Multaq (dronedarone)
    +
    edoxaban
    1 interaction

    Monitor/Modify Tx

    dronedarone + edoxaban

    monitor bleeding s/sx; decr. edoxaban dose to 30 mg/day in DVT/PE pts; no dose adjustment recommended in atrial fibrillation pts: combo may incr. edoxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport inhibited)

  • elexacaftor/tezacaftor/ivacaftor
  • Multaq (dronedarone)
    +
    elexacaftor/ tezacaftor/ ivacaftor
    1 interaction

    Monitor/Modify Tx

    dronedarone + elexacaftor/ tezacaftor/ ivacaftor

    2-5 YO: decr. usual morning dose by alternating between one elexacaftor/tezacaftor/ivacaftor packet (Day 1) and one ivacaftor packet (Day 2), no evening doses; 6 YO AND OLDER: decr. usual morning dose by alternating between two elexacaftor/tezacaftor/ivacaftor tablets (Day 1) and one ivacaftor tablet (Day 2), no evening doses: combo may incr. elexacaftor/tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

  • elinzanetant
  • Multaq (dronedarone)
    +
    elinzanetant
    1 interaction

    Monitor/Modify Tx

    dronedarone + elinzanetant

    decr. elinzanetant dose to 60 mg daily: combo may incr. elinzanetant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • enfortumab vedotin
  • Multaq (dronedarone)
    +
    enfortumab vedotin
    1 interaction

    Monitor/Modify Tx

    dronedarone + enfortumab vedotin

    if also combined w/ strong CYP3A4 inhibitor, monitor CBC, glucose: combo may incr. enfortumab vedotin levels, risk of myelosuppression, neuropathy, hyperglycemia, other adverse effects (P-gp-mediated transport inhibited)

  • epinephrine
  • Multaq (dronedarone)
    +
    epinephrine
    1 interaction

    Monitor/Modify Tx

    dronedarone + epinephrine

    monitor ECG: combo may incr. risk of cardiac arrhythmias (additive effects)

  • eplerenone
  • Multaq (dronedarone)
    +
    eplerenone
    1 interaction

    Monitor/Modify Tx

    dronedarone + eplerenone

    ALL INDICATIONS: monitor potassium, renal fxn; POST-MI HFrEF: adjust max eplerenone dose to 25 mg/day; HTN: start eplerenone 25 mg qd, adjust max eplerenone dose to 50 mg/day: combo may incr. eplerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

  • erdafitinib
  • Multaq (dronedarone)
    +
    erdafitinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + erdafitinib

    monitor phosphate: combo may incr. erdafitinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

  • esmolol
  • Multaq (dronedarone)
    +
    esmolol
    1 interaction

    Monitor/Modify Tx

    dronedarone + esmolol

    start w/ low esmolol dose, monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • estazolam
  • Multaq (dronedarone)
    +
    estazolam
    1 interaction

    Monitor/Modify Tx

    dronedarone + estazolam

    monitor respiratory rate; consider decr. estazolam dose: combo may incr. estazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • estradiol (contraceptive)
  • Multaq (dronedarone)
    +
    estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    dronedarone + estradiol (contraceptive)

    monitor thrombosis s/sx: combo may incr. estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • ethinyl estradiol (contraceptive)
  • Multaq (dronedarone)
    +
    ethinyl estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    dronedarone + ethinyl estradiol (contraceptive)

    monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

  • etoposide
  • Multaq (dronedarone)
    +
    etoposide
    1 interaction

    Monitor/Modify Tx

    dronedarone + etoposide

    monitor CBC: combo may incr. etoposide levels, risk of serious infection, myelosuppression, other adverse effects (P-gp-mediated transport inhibited)

  • etripamil nasal
  • Multaq (dronedarone)
    +
    etripamil nasal
    1 interaction

    Monitor/Modify Tx

    dronedarone + etripamil nasal

    monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • everolimus
  • Multaq (dronedarone)
    +
    everolimus
    1 interaction

    Monitor/Modify Tx

    dronedarone + everolimus

    BREAST CA, PNET, RENAL CELL CA, or RENAL ANGIOMYOLIPOMA w/ TSC: decr. everolimus dose to 2.5 mg/day, may then incr. to 5 mg/day if tolerated, monitor CBC; TSC-ASSOC. SEGA or TSC-ASSOC. PARTIAL-ONSET SEIZURES: monitor everolimus levels, CBC and decr. everolimus dose 50%; give every other day if already on lowest available dose; TRANSPLANT: monitor everolimus levels, CBC: combo may incr. everolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • fam-trastuzumab deruxtecan
  • Multaq (dronedarone)
    +
    fam-trastuzumab deruxtecan
    1 interaction

    Monitor/Modify Tx

    dronedarone + fam-trastuzumab deruxtecan

    monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

  • fedratinib
  • Multaq (dronedarone)
    +
    fedratinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + fedratinib

    monitor ECG; if fedratinib also combined w/ CYP2C19 inhibitor, monitor CBC, LFTs: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

  • felodipine
  • Multaq (dronedarone)
    +
    felodipine
    1 interaction

    Monitor/Modify Tx

    dronedarone + felodipine

    start w/ low felodipine dose, monitor BP, HR, ECG: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • finerenone
  • Multaq (dronedarone)
    +
    finerenone
    1 interaction

    Monitor/Modify Tx

    dronedarone + finerenone

    monitor potassium: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metabolism inhibited)

  • fosamprenavir
  • Multaq (dronedarone)
    +
    fosamprenavir
    1 interaction

    Monitor/Modify Tx

    dronedarone + fosamprenavir

    monitor ECG: combo may incr. or decr. dronedarone levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism altered)

  • futibatinib
  • Multaq (dronedarone)
    +
    futibatinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + futibatinib

    monitor phosphate: combo may incr. futibatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

  • gadobenate dimeglumine
  • Multaq (dronedarone)
    +
    gadobenate dimeglumine
    1 interaction

    Monitor/Modify Tx

    dronedarone + gadobenate dimeglumine

    monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • galantamine
  • Multaq (dronedarone)
    +
    galantamine
    1 interaction

    Monitor/Modify Tx

    dronedarone + galantamine

    monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • guanfacine
  • Multaq (dronedarone)
    +
    guanfacine
    1 interaction

    Monitor/Modify Tx

    dronedarone + guanfacine

    monitor HR, ECG; decr. guanfacine ER dose 50%, consider decr. dose for immed.-release form: combo may incr. guanfacine levels, risk of PR interval prolongation, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • hydrocortisone
  • Multaq (dronedarone)
    +
    hydrocortisone
    1 interaction

    Monitor/Modify Tx

    dronedarone + hydrocortisone

    consider decr. hydrocortisone dose: combo may incr. hydrocortisone levels, risk of systemic corticosteroid effects, including Cushing syndrome and adrenal suppression, other adverse effects (hepatic metabolism inhibited)

  • ibrutinib
  • Multaq (dronedarone)
    +
    ibrutinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + ibrutinib

    monitor cardiac fxn; B-CELL MALIGNANCIES: decr. ibrutinib dose to 280 mg qd; CHRONIC GVHD: consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • ifosfamide
  • Multaq (dronedarone)
    +
    ifosfamide
    1 interaction

    Monitor/Modify Tx

    dronedarone + ifosfamide

    monitor cardiac fxn: combo may decr. ifosfamide active metabolite levels, efficacy; may incr. risk of cardiotoxicity (hepatic metabolism inhibited, decr. active metabolite formation; additive effects)

  • imatinib
  • Multaq (dronedarone)
    +
    imatinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + imatinib

    monitor ECG, cardiac fxn: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, cardiotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • infliximab
  • Multaq (dronedarone)
    +
    infliximab
    1 interaction

    Monitor/Modify Tx

    dronedarone + infliximab

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • interferon beta 1a
  • Multaq (dronedarone)
    +
    interferon beta 1a
    1 interaction

    Monitor/Modify Tx

    dronedarone + interferon beta 1a

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • interferon beta 1b
  • Multaq (dronedarone)
    +
    interferon beta 1b
    1 interaction

    Monitor/Modify Tx

    dronedarone + interferon beta 1b

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • interferon gamma 1b
  • Multaq (dronedarone)
    +
    interferon gamma 1b
    1 interaction

    Monitor/Modify Tx

    dronedarone + interferon gamma 1b

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • irinotecan
  • Multaq (dronedarone)
    +
    irinotecan
    1 interaction

    Monitor/Modify Tx

    dronedarone + irinotecan

    monitor CBC: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (hepatic metabolism inhibited)

  • isavuconazonium
  • Multaq (dronedarone)
    +
    isavuconazonium
    1 interaction

    Monitor/Modify Tx

    dronedarone + isavuconazonium

    monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • isradipine
  • Multaq (dronedarone)
    +
    isradipine
    1 interaction

    Monitor/Modify Tx

    dronedarone + isradipine

    start w/ low isradipine dose; monitor HR, ECG: combo may incr. risk of bradycardia (additive effects)

  • labetalol
  • Multaq (dronedarone)
    +
    labetalol
    1 interaction

    Monitor/Modify Tx

    dronedarone + labetalol

    start w/ low labetalol dose, monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • lacosamide
  • Multaq (dronedarone)
    +
    lacosamide
    1 interaction

    Monitor/Modify Tx

    dronedarone + lacosamide

    monitor HR, ECG, especially during lacosamide initiation/titration: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • lamotrigine
  • Multaq (dronedarone)
    +
    lamotrigine
    1 interaction

    Monitor/Modify Tx

    dronedarone + lamotrigine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • larotrectinib
  • Multaq (dronedarone)
    +
    larotrectinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + larotrectinib

    caution advised: combo may incr. larotrectinib levels, risk of adverse effects (hepatic metabolism inhibited; P-gp-mediated transport inhibited)

  • letermovir
  • Multaq (dronedarone)
    +
    letermovir
    1 interaction

    Monitor/Modify Tx

    dronedarone + letermovir

    monitor ECG: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

  • levobunolol ophthalmic
  • Multaq (dronedarone)
    +
    levobunolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    dronedarone + levobunolol ophthalmic

    monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • lidocaine
  • Multaq (dronedarone)
    +
    lidocaine
    1 interaction

    Monitor/Modify Tx

    dronedarone + lidocaine

    monitor lidocaine levels if lidocaine antiarrhythmic use; otherwise, monitor BP, HR: combo may incr. lidocaine levels, risk of hypotension, bradycardia, other adverse effects; risk may be higher with continuous infusion or higher doses for local anesthesia (hepatic metabolism inhibited, additive effects)

  • linagliptin
  • Multaq (dronedarone)
    +
    linagliptin
    1 interaction

    Monitor/Modify Tx

    dronedarone + linagliptin

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • lumateperone
  • Multaq (dronedarone)
    +
    lumateperone
    1 interaction

    Monitor/Modify Tx

    dronedarone + lumateperone

    monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited, additive effects)

  • margetuximab
  • Multaq (dronedarone)
    +
    margetuximab
    1 interaction

    Monitor/Modify Tx

    dronedarone + margetuximab

    monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

  • mepivacaine
  • Multaq (dronedarone)
    +
    mepivacaine
    1 interaction

    Monitor/Modify Tx

    dronedarone + mepivacaine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • metoprolol
  • Multaq (dronedarone)
    +
    metoprolol
    1 interaction

    Monitor/Modify Tx

    dronedarone + metoprolol

    start w/ low metoprolol dose, monitor BP, HR, ECG: combo may incr. metoprolol levels, risk of hypotension, PR interval prolongation, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • midodrine
  • Multaq (dronedarone)
    +
    midodrine
    1 interaction

    Monitor/Modify Tx

    dronedarone + midodrine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • mirdametinib
  • Multaq (dronedarone)
    +
    mirdametinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + mirdametinib

    monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

  • mitoxantrone
  • Multaq (dronedarone)
    +
    mitoxantrone
    1 interaction

    Monitor/Modify Tx

    dronedarone + mitoxantrone

    monitor CBC, cardiac fxn, incl. LVEF: combo may incr. mitoxantrone levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (P-gp-mediated transport inhibited, additive effects)

  • morphine
  • Multaq (dronedarone)
    +
    morphine
    1 interaction

    Monitor/Modify Tx

    dronedarone + morphine

    monitor respiratory rate, consider decr. dose of one or both drugs: combo may incr. morphine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (P-gp-mediated transport inhibited)

  • nadolol
  • Multaq (dronedarone)
    +
    nadolol
    1 interaction

    Monitor/Modify Tx

    dronedarone + nadolol

    start w/ low nadolol dose, monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • nebivolol
  • Multaq (dronedarone)
    +
    nebivolol
    1 interaction

    Monitor/Modify Tx

    dronedarone + nebivolol

    start w/ low nebivolol dose, monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • neostigmine
  • Multaq (dronedarone)
    +
    neostigmine
    1 interaction

    Monitor/Modify Tx

    dronedarone + neostigmine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • nifedipine
  • Multaq (dronedarone)
    +
    nifedipine
    1 interaction

    Monitor/Modify Tx

    dronedarone + nifedipine

    monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects (hepatic metabolism inhibited)

  • nimodipine
  • Multaq (dronedarone)
    +
    nimodipine
    1 interaction

    Monitor/Modify Tx

    dronedarone + nimodipine

    start w/ low nimodipine dose, monitor HR, ECG: combo may incr. nimodipine levels, risk of hypotension, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • nintedanib
  • Multaq (dronedarone)
    +
    nintedanib
    1 interaction

    Monitor/Modify Tx

    dronedarone + nintedanib

    consider decr. nintedanib dose: combo may incr. nintedanib levels, risk of adverse effects (P-gp-mediated transport inhibited)

  • nortriptyline
  • Multaq (dronedarone)
    +
    nortriptyline
    1 interaction

    Monitor/Modify Tx

    dronedarone + nortriptyline

    monitor nortriptyline levels: combo may incr. nortriptyline levels, risk of adverse effects (hepatic metabolism inhibited)

  • octreotide
  • Multaq (dronedarone)
    +
    octreotide
    1 interaction

    Monitor/Modify Tx

    dronedarone + octreotide

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • paclitaxel
  • Multaq (dronedarone)
    +
    paclitaxel
    1 interaction

    Monitor/Modify Tx

    dronedarone + paclitaxel

    monitor CBC: combo may incr. paclitaxel levels, risk of serious infection, myelosuppression, other adverse effects (P-gp-mediated transport inhibited)

  • palbociclib
  • Multaq (dronedarone)
    +
    palbociclib
    1 interaction

    Monitor/Modify Tx

    dronedarone + palbociclib

    monitor CBC: combo may incr. palbociclib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • paltusotine
  • Multaq (dronedarone)
    +
    paltusotine
    1 interaction

    Monitor/Modify Tx

    dronedarone + paltusotine

    monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • peginterferon beta 1a
  • Multaq (dronedarone)
    +
    peginterferon beta 1a
    1 interaction

    Monitor/Modify Tx

    dronedarone + peginterferon beta 1a

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • pertuzumab
  • Multaq (dronedarone)
    +
    pertuzumab
    1 interaction

    Monitor/Modify Tx

    dronedarone + pertuzumab

    monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

  • pindolol
  • Multaq (dronedarone)
    +
    pindolol
    1 interaction

    Monitor/Modify Tx

    dronedarone + pindolol

    start w/ low pindolol dose, monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • pirtobrutinib
  • Multaq (dronedarone)
    +
    pirtobrutinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + pirtobrutinib

    monitor CBC: combo may incr. pirtobrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • pitavastatin
  • Multaq (dronedarone)
    +
    pitavastatin
    1 interaction

    Monitor/Modify Tx

    dronedarone + pitavastatin

    monitor CK, myopathy sx: combo may incr. pitavastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (P-gp-mediated transport inhibited)

  • ponatinib
  • Multaq (dronedarone)
    +
    ponatinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + ponatinib

    monitor CBC, cardiac fxn: combo may incr. ponatinib levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • pravastatin
  • Multaq (dronedarone)
    +
    pravastatin
    1 interaction

    Monitor/Modify Tx

    dronedarone + pravastatin

    monitor CK, myopathy sx: combo may incr. pravastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (P-gp-mediated transport inhibited)

  • praziquantel
  • Multaq (dronedarone)
    +
    praziquantel
    1 interaction

    Monitor/Modify Tx

    dronedarone + praziquantel

    monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • propofol
  • Multaq (dronedarone)
    +
    propofol
    1 interaction

    Monitor/Modify Tx

    dronedarone + propofol

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • propranolol
  • Multaq (dronedarone)
    +
    propranolol
    1 interaction

    Monitor/Modify Tx

    dronedarone + propranolol

    start w/ low propranolol dose; monitor HR, ECG, BP: combo may incr. propranolol levels, risk of hypotension, PR interval prolongation, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • pyridostigmine
  • Multaq (dronedarone)
    +
    pyridostigmine
    1 interaction

    Monitor/Modify Tx

    dronedarone + pyridostigmine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • red yeast rice
  • Multaq (dronedarone)
    +
    red yeast rice
    1 interaction

    Monitor/Modify Tx

    dronedarone + red yeast rice

    monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, red yeast rice contains varying amounts of lovastatin)

  • remimazolam
  • Multaq (dronedarone)
    +
    remimazolam
    1 interaction

    Monitor/Modify Tx

    dronedarone + remimazolam

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • repaglinide
  • Multaq (dronedarone)
    +
    repaglinide
    1 interaction

    Monitor/Modify Tx

    dronedarone + repaglinide

    monitor glucose: combo may incr. repaglinide levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

  • rimegepant
  • Multaq (dronedarone)
    +
    rimegepant
    1 interaction

    Monitor/Modify Tx

    dronedarone + rimegepant

    separate rimegepant doses by at least 48h: combo may incr. rimegepant levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • riociguat
  • Multaq (dronedarone)
    +
    riociguat
    1 interaction

    Monitor/Modify Tx

    dronedarone + riociguat

    consider decr. riociguat start dose to 0.5 mg PO tid; monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • ripretinib
  • Multaq (dronedarone)
    +
    ripretinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + ripretinib

    monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

  • rivastigmine
  • Multaq (dronedarone)
    +
    rivastigmine
    1 interaction

    Monitor/Modify Tx

    dronedarone + rivastigmine

    monitor HR: combo may increase risk of bradycardia (additive effects)

  • ropeginterferon alfa-2b
  • Multaq (dronedarone)
    +
    ropeginterferon alfa-2b
    1 interaction

    Monitor/Modify Tx

    dronedarone + ropeginterferon alfa-2b

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • ropivacaine
  • Multaq (dronedarone)
    +
    ropivacaine
    1 interaction

    Monitor/Modify Tx

    dronedarone + ropivacaine

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • ruxolitinib
  • Multaq (dronedarone)
    +
    ruxolitinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + ruxolitinib

    monitor CBC: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • ruxolitinib topical
  • Multaq (dronedarone)
    +
    ruxolitinib topical
    1 interaction

    Monitor/Modify Tx

    dronedarone + ruxolitinib topical

    monitor CBC: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • salmeterol inhaled
  • Multaq (dronedarone)
    +
    salmeterol inhaled
    1 interaction

    Monitor/Modify Tx

    dronedarone + salmeterol inhaled

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • saxagliptin
  • Multaq (dronedarone)
    +
    saxagliptin
    1 interaction

    Monitor/Modify Tx

    dronedarone + saxagliptin

    monitor glucose, cardiac fxn: combo may incr. saxagliptin levels, risk of hypoglycemia, cardiotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • sildenafil
  • Multaq (dronedarone)
    +
    sildenafil
    1 interaction

    Monitor/Modify Tx

    dronedarone + sildenafil

    monitor BP: combo may incr. sildenafil levels, risk of hypotension (including syncope), priapism, other adverse effects (hepatic metabolism inhibited)

  • sitagliptin
  • Multaq (dronedarone)
    +
    sitagliptin
    1 interaction

    Monitor/Modify Tx

    dronedarone + sitagliptin

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • sparsentan
  • Multaq (dronedarone)
    +
    sparsentan
    1 interaction

    Monitor/Modify Tx

    dronedarone + sparsentan

    monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

  • sugammadex
  • Multaq (dronedarone)
    +
    sugammadex
    1 interaction

    Monitor/Modify Tx

    dronedarone + sugammadex

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • suvorexant
  • Multaq (dronedarone)
    +
    suvorexant
    1 interaction

    Monitor/Modify Tx

    dronedarone + suvorexant

    decr. suvorexant dose to 5 mg, max 10 mg/day: combo may incr. suvorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • suzetrigine
  • Multaq (dronedarone)
    +
    suzetrigine
    1 interaction

    Monitor/Modify Tx

    dronedarone + suzetrigine

    start suzetrigine 100 mg x1 at least 1h before or 2h after food, after 12h give 50 mg q12h x3 doses, then after 12h give 50mg q24h: combo may incr. suzetrigine and active metabolite levels, risk of adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

  • tadalafil
  • Multaq (dronedarone)
    +
    tadalafil
    1 interaction

    Monitor/Modify Tx

    dronedarone + tadalafil

    monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

  • talazoparib
  • Multaq (dronedarone)
    +
    talazoparib
    1 interaction

    Monitor/Modify Tx

    dronedarone + talazoparib

    decr. talazoparib dose to 0.75 mg qd, monitor CBC: combo may incr. talazoparib levels, risk of myelosuppression, other adverse effects (P-gp-mediated transport inhibited)

  • tamsulosin
  • Multaq (dronedarone)
    +
    tamsulosin
    1 interaction

    Monitor/Modify Tx

    dronedarone + tamsulosin

    monitor BP, especially w/ tamsulosin dose >0.4 mg: combo may incr. tamsulosin levels, risk of hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited)

  • temsirolimus
  • Multaq (dronedarone)
    +
    temsirolimus
    1 interaction

    Monitor/Modify Tx

    dronedarone + temsirolimus

    monitor CBC; consider decr. temsirolimus dose: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • tenofovir alafenamide
  • Multaq (dronedarone)
    +
    tenofovir alafenamide
    1 interaction

    Monitor/Modify Tx

    dronedarone + tenofovir alafenamide

    if tenofovir alafenamide not admin. w/ cobicistat, monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited)

  • tenofovir disoproxil
  • Multaq (dronedarone)
    +
    tenofovir disoproxil
    1 interaction

    Monitor/Modify Tx

    dronedarone + tenofovir disoproxil

    monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport inhibited)

  • tezacaftor/ivacaftor
  • Multaq (dronedarone)
    +
    tezacaftor/ ivacaftor
    1 interaction

    Monitor/Modify Tx

    dronedarone + tezacaftor/ ivacaftor

    decr. dose by alternating tezacaftor/ivacaftor tab and ivacaftor tab at morning dose, no evening doses: combo may incr. tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

  • thalidomide
  • Multaq (dronedarone)
    +
    thalidomide
    1 interaction

    Monitor/Modify Tx

    dronedarone + thalidomide

    monitor HR: combo may incr. risk of bradycardia (additive effects)

  • ticagrelor
  • Multaq (dronedarone)
    +
    ticagrelor
    1 interaction

    Monitor/Modify Tx

    dronedarone + ticagrelor

    monitor HR, ECG: combo may incr. ticagrelor levels, risk of dyspnea, bleeding, PR interval prolongation, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited, additive effects)

  • timolol
  • Multaq (dronedarone)
    +
    timolol
    1 interaction

    Monitor/Modify Tx

    dronedarone + timolol

    start w/ low timolol dose, monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • timolol ophthalmic
  • Multaq (dronedarone)
    +
    timolol ophthalmic
    1 interaction

    Monitor/Modify Tx

    dronedarone + timolol ophthalmic

    monitor HR, ECG: combo may incr. risk of PR interval prolongation, AV block, bradycardia (additive effects)

  • tivozanib
  • Multaq (dronedarone)
    +
    tivozanib
    1 interaction

    Monitor/Modify Tx

    dronedarone + tivozanib

    monitor cardiac fxn: combo may incr. risk of cardiotoxicity (additive effects)

  • tofacitinib
  • Multaq (dronedarone)
    +
    tofacitinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + tofacitinib

    ALL USES: monitor CBC; if also combined w/ strong CYP2C19 inhibitor, adjust tofacitinib as follows: ADULT RHEUMATOID or PSORIATIC ARTHRITIS or ANKYLOSING SPONDYLITIS: decr. to 5 mg qd; ADULT ULCERATIVE COLITIS: decr. induction to 5 mg bid using tabs or 11 mg qd using XR tab for up to 16 wks, followed by 5 mg qd maintenance using tabs; do not use XR tabs for maintenance doses; PEDIATRIC PSORIATIC ARTHRITIS, POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: decr. usual bid dose to qd: combo may incr. tofacitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • trabectedin
  • Multaq (dronedarone)
    +
    trabectedin
    1 interaction

    Monitor/Modify Tx

    dronedarone + trabectedin

    monitor CBC, cardiac function (including LVEF), LFTs: combo may incr. trabectedin levels, risk of myelosuppression, cardiotoxicity, hepatotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

  • trastuzumab
  • Multaq (dronedarone)
    +
    trastuzumab
    1 interaction

    Monitor/Modify Tx

    dronedarone + trastuzumab

    monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

  • triazolam
  • Multaq (dronedarone)
    +
    triazolam
    1 interaction

    Monitor/Modify Tx

    dronedarone + triazolam

    monitor respiratory rate; consider decr. triazolam dose: combo may incr. triazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

  • ubrogepant
  • Multaq (dronedarone)
    +
    ubrogepant
    1 interaction

    Monitor/Modify Tx

    dronedarone + ubrogepant

    limit ubrogepant dose to 50 mg, may give second 50 mg dose after 24h if needed: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • vanzacaftor/tezacaftor/deutivacaftor
  • Multaq (dronedarone)
    +
    vanzacaftor/ tezacaftor/ deutivacaftor
    1 interaction

    Monitor/Modify Tx

    dronedarone + vanzacaftor/ tezacaftor/ deutivacaftor

    6-11 YO AND WT <40 KG: decr. vanzacaftor/tezacaftor/deutivacaftor dose to two tablets (4 mg/20 mg/50 mg each) qod; 6-11 YO AND WT 40 KG AND ABOVE: decr. vanzacaftor/tezacaftor/deutivacaftor dose to one tablet (10 mg/50 mg/125 mg) qod; 12 YO AND OLDER: decr. vanzacaftor/tezacaftor/deutivacaftor dose to one tablet (10 mg/50 mg/125 mg) qod: combo may incr. vanzacaftor/tezacaftor/deutivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

  • verapamil
  • Multaq (dronedarone)
    +
    verapamil
    1 interaction

    Monitor/Modify Tx

    dronedarone + verapamil

    start w/ low verapamil dose; monitor BP, HR, ECG: combo may incr. levels of both drugs, risk of QT and PR interval prolongation, cardiac arrhythmias, hypotension, AV block, bradycardia, other adverse effects (hepatic metabolism inhibited, additive effects)

  • vinblastine
  • Multaq (dronedarone)
    +
    vinblastine
    1 interaction

    Monitor/Modify Tx

    dronedarone + vinblastine

    monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

  • vincristine
  • Multaq (dronedarone)
    +
    vincristine
    1 interaction

    Monitor/Modify Tx

    dronedarone + vincristine

    monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

  • vinorelbine
  • Multaq (dronedarone)
    +
    vinorelbine
    1 interaction

    Monitor/Modify Tx

    dronedarone + vinorelbine

    monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited)

  • warfarin
  • Multaq (dronedarone)
    +
    warfarin
    1 interaction

    Monitor/Modify Tx

    dronedarone + warfarin

    monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited)

  • zanidatamab
  • Multaq (dronedarone)
    +
    zanidatamab
    1 interaction

    Monitor/Modify Tx

    dronedarone + zanidatamab

    monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

  • zanubrutinib
  • Multaq (dronedarone)
    +
    zanubrutinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + zanubrutinib

    decr. zanubrutinib dose to 80 mg bid; monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

  • zenocutuzumab
  • Multaq (dronedarone)
    +
    zenocutuzumab
    1 interaction

    Monitor/Modify Tx

    dronedarone + zenocutuzumab

    monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

  • zongertinib
  • Multaq (dronedarone)
    +
    zongertinib
    1 interaction

    Monitor/Modify Tx

    dronedarone + zongertinib

    monitor cardiac fxn, incl. LVEF: combo may incr. risk of cardiotoxicity (additive effects)

Caution Advised

  • aliskiren
  • Multaq (dronedarone)
    +
    aliskiren
    1 interaction

    Caution Advised

    dronedarone + aliskiren

    caution advised: combo may incr. aliskiren levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • armodafinil
  • Multaq (dronedarone)
    +
    armodafinil
    1 interaction

    Caution Advised

    dronedarone + armodafinil

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • belzutifan
  • Multaq (dronedarone)
    +
    belzutifan
    1 interaction

    Caution Advised

    dronedarone + belzutifan

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • bexarotene
  • Multaq (dronedarone)
    +
    bexarotene
    1 interaction

    Caution Advised

    dronedarone + bexarotene

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • budesonide rectal
  • Multaq (dronedarone)
    +
    budesonide rectal
    1 interaction

    Caution Advised

    dronedarone + budesonide rectal

    caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited)

  • clobazam
  • Multaq (dronedarone)
    +
    clobazam
    1 interaction

    Caution Advised

    dronedarone + clobazam

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • danshen
  • Multaq (dronedarone)
    +
    danshen
    1 interaction

    Caution Advised

    dronedarone + danshen

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • darifenacin
  • Multaq (dronedarone)
    +
    darifenacin
    1 interaction

    Caution Advised

    dronedarone + darifenacin

    caution advised: combo may incr. darifenacin levels, risk of adverse effects (hepatic metabolism inhibited)

  • darolutamide
  • Multaq (dronedarone)
    +
    darolutamide
    1 interaction

    Caution Advised

    dronedarone + darolutamide

    caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. dronedarone levels, efficacy (P-gp-mediated transport inhibited; hepatic metabolism induced)

  • dexamethasone
  • Multaq (dronedarone)
    +
    dexamethasone
    1 interaction

    Caution Advised

    dronedarone + dexamethasone

    caution advised: combo may incr. dexamethasone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

  • dicloxacillin
  • Multaq (dronedarone)
    +
    dicloxacillin
    1 interaction

    Caution Advised

    dronedarone + dicloxacillin

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • echinacea
  • Multaq (dronedarone)
    +
    echinacea
    1 interaction

    Caution Advised

    dronedarone + echinacea

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • elafibranor
  • Multaq (dronedarone)
    +
    elafibranor
    1 interaction

    Caution Advised

    dronedarone + elafibranor

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • elagolix
  • Multaq (dronedarone)
    +
    elagolix
    1 interaction

    Caution Advised

    dronedarone + elagolix

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • eletriptan
  • Multaq (dronedarone)
    +
    eletriptan
    1 interaction

    Caution Advised

    dronedarone + eletriptan

    caution advised: combo may incr. eletriptan levels, risk of adverse effects (hepatic metabolism inhibited)

  • enasidenib
  • Multaq (dronedarone)
    +
    enasidenib
    1 interaction

    Caution Advised

    dronedarone + enasidenib

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • erlotinib
  • Multaq (dronedarone)
    +
    erlotinib
    1 interaction

    Caution Advised

    dronedarone + erlotinib

    caution advised: combo may incr. erlotinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • eslicarbazepine acetate
  • Multaq (dronedarone)
    +
    eslicarbazepine acetate
    1 interaction

    Caution Advised

    dronedarone + eslicarbazepine acetate

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • felbamate
  • Multaq (dronedarone)
    +
    felbamate
    1 interaction

    Caution Advised

    dronedarone + felbamate

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • garlic
  • Multaq (dronedarone)
    +
    garlic
    1 interaction

    Caution Advised

    dronedarone + garlic

    caution advised w/ supplemental garlic; dietary intake OK: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • ginkgo
  • Multaq (dronedarone)
    +
    ginkgo
    1 interaction

    Caution Advised

    dronedarone + ginkgo

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • ginseng, Asian
  • Multaq (dronedarone)
    +
    ginseng, Asian
    1 interaction

    Caution Advised

    dronedarone + ginseng, Asian

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • glecaprevir
  • Multaq (dronedarone)
    +
    glecaprevir
    1 interaction

    Caution Advised

    dronedarone + glecaprevir

    caution advised: combo may incr. glecaprevir levels, risk of adverse effects (P-gp-mediated transport inhibited)

  • glycerol phenylbutyrate
  • Multaq (dronedarone)
    +
    glycerol phenylbutyrate
    1 interaction

    Caution Advised

    dronedarone + glycerol phenylbutyrate

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • grazoprevir
  • Multaq (dronedarone)
    +
    grazoprevir
    1 interaction

    Caution Advised

    dronedarone + grazoprevir

    caution advised: combo may incr. grazoprevir levels, risk of adverse effects (hepatic metabolism inhibited)

  • griseofulvin
  • Multaq (dronedarone)
    +
    griseofulvin
    1 interaction

    Caution Advised

    dronedarone + griseofulvin

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • imlunestrant
  • Multaq (dronedarone)
    +
    imlunestrant
    1 interaction

    Caution Advised

    dronedarone + imlunestrant

    caution advised: combo may incr. imlunestrant levels, risk of adverse effects (hepatic metabolism inhibited)

  • istradefylline
  • Multaq (dronedarone)
    +
    istradefylline
    1 interaction

    Caution Advised

    dronedarone + istradefylline

    caution advised: combo may incr. istradefylline levels, risk of adverse effects (hepatic metabolism inhibited)

  • maraviroc
  • Multaq (dronedarone)
    +
    maraviroc
    1 interaction

    Caution Advised

    dronedarone + maraviroc

    caution advised: combo may incr. maraviroc levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • meropenem
  • Multaq (dronedarone)
    +
    meropenem
    1 interaction

    Caution Advised

    dronedarone + meropenem

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism possibly induced)

  • methylprednisolone
  • Multaq (dronedarone)
    +
    methylprednisolone
    1 interaction

    Caution Advised

    dronedarone + methylprednisolone

    caution advised: combo may incr. methylprednisolone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression (hepatic metabolism inhibited)

  • naldemedine
  • Multaq (dronedarone)
    +
    naldemedine
    1 interaction

    Caution Advised

    dronedarone + naldemedine

    caution advised: combo may incr. naldemedine levels, risk of adverse effects (hepatic metabolism inhibited, P-gp-mediated transport inhibited)

  • nevirapine
  • Multaq (dronedarone)
    +
    nevirapine
    1 interaction

    Caution Advised

    dronedarone + nevirapine

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • odevixibat
  • Multaq (dronedarone)
    +
    odevixibat
    1 interaction

    Caution Advised

    dronedarone + odevixibat

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • olutasidenib
  • Multaq (dronedarone)
    +
    olutasidenib
    1 interaction

    Caution Advised

    dronedarone + olutasidenib

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism possibly induced)

  • ospemifene
  • Multaq (dronedarone)
    +
    ospemifene
    1 interaction

    Caution Advised

    dronedarone + ospemifene

    caution advised: combo may incr. ospemifene levels, risk of adverse effects (hepatic metabolism inhibited)

  • oxcarbazepine
  • Multaq (dronedarone)
    +
    oxcarbazepine
    1 interaction

    Caution Advised

    dronedarone + oxcarbazepine

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • perampanel
  • Multaq (dronedarone)
    +
    perampanel
    1 interaction

    Caution Advised

    dronedarone + perampanel

    caution advised if on perampanel 12 mg/day: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • perphenazine
  • Multaq (dronedarone)
    +
    perphenazine
    1 interaction

    Caution Advised

    dronedarone + perphenazine

    caution advised: combo may incr. perphenazine levels, risk of adverse effects (hepatic metabolism inhibited)

  • pibrentasvir
  • Multaq (dronedarone)
    +
    pibrentasvir
    1 interaction

    Caution Advised

    dronedarone + pibrentasvir

    caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport inhibited)

  • pioglitazone
  • Multaq (dronedarone)
    +
    pioglitazone
    1 interaction

    Caution Advised

    dronedarone + pioglitazone

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • prednisone
  • Multaq (dronedarone)
    +
    prednisone
    1 interaction

    Caution Advised

    dronedarone + prednisone

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • rifaximin
  • Multaq (dronedarone)
    +
    rifaximin
    1 interaction

    Caution Advised

    dronedarone + rifaximin

    caution advised: combo may incr. rifaximin levels, risk of adverse effects (P-gp-mediated transport inhibited)

  • roflumilast
  • Multaq (dronedarone)
    +
    roflumilast
    1 interaction

    Caution Advised

    dronedarone + roflumilast

    caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

  • roflumilast topical
  • Multaq (dronedarone)
    +
    roflumilast topical
    1 interaction

    Caution Advised

    dronedarone + roflumilast topical

    caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

  • rufinamide
  • Multaq (dronedarone)
    +
    rufinamide
    1 interaction

    Caution Advised

    dronedarone + rufinamide

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • sarilumab
  • Multaq (dronedarone)
    +
    sarilumab
    1 interaction

    Caution Advised

    dronedarone + sarilumab

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C)

  • seladelpar
  • Multaq (dronedarone)
    +
    seladelpar
    1 interaction

    Caution Advised

    dronedarone + seladelpar

    caution advised if CYP2C9 poor metabolizer or if also combined w/ moderate CYP2C9 inhibitor: combo may incr. seladelpar levels, risk of adverse effects (hepatic metabolism inhibited)

  • sevabertinib
  • Multaq (dronedarone)
    +
    sevabertinib
    1 interaction

    Caution Advised

    dronedarone + sevabertinib

    caution advised: combo may incr. sevabertinib levels, risk of adverse effects (hepatic metabolism inhibited)

  • sirolimus topical
  • Multaq (dronedarone)
    +
    sirolimus topical
    1 interaction

    Caution Advised

    dronedarone + sirolimus topical

    caution advised: combo may incr. sirolimus levels, risk of adverse effects (hepatic metabolism inhibited)

  • stiripentol
  • Multaq (dronedarone)
    +
    stiripentol
    1 interaction

    Caution Advised

    dronedarone + stiripentol

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism possibly induced)

  • sunvozertinib
  • Multaq (dronedarone)
    +
    sunvozertinib
    1 interaction

    Caution Advised

    dronedarone + sunvozertinib

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • tecovirimat
  • Multaq (dronedarone)
    +
    tecovirimat
    1 interaction

    Caution Advised

    dronedarone + tecovirimat

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • telotristat ethyl
  • Multaq (dronedarone)
    +
    telotristat ethyl
    1 interaction

    Caution Advised

    dronedarone + telotristat ethyl

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • tocilizumab
  • Multaq (dronedarone)
    +
    tocilizumab
    1 interaction

    Caution Advised

    dronedarone + tocilizumab

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes)

  • topiramate
  • Multaq (dronedarone)
    +
    topiramate
    1 interaction

    Caution Advised

    dronedarone + topiramate

    caution advised, especially w/ topiramate doses >200 mg/day: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • tovorafenib
  • Multaq (dronedarone)
    +
    tovorafenib
    1 interaction

    Caution Advised

    dronedarone + tovorafenib

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism induced)

  • tretinoin
  • Multaq (dronedarone)
    +
    tretinoin
    1 interaction

    Caution Advised

    dronedarone + tretinoin

    caution advised: combo may incr. tretinoin levels, risk of adverse effects (hepatic metabolism inhibited)

  • upadacitinib
  • Multaq (dronedarone)
    +
    upadacitinib
    1 interaction

    Caution Advised

    dronedarone + upadacitinib

    caution advised: combo may incr. upadacitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited)

  • vaborbactam
  • Multaq (dronedarone)
    +
    vaborbactam
    1 interaction

    Caution Advised

    dronedarone + vaborbactam

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism possibly induced)

  • vamorolone
  • Multaq (dronedarone)
    +
    vamorolone
    1 interaction

    Caution Advised

    dronedarone + vamorolone

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism possibly induced)

  • vilazodone
  • Multaq (dronedarone)
    +
    vilazodone
    1 interaction

    Caution Advised

    dronedarone + vilazodone

    caution advised: combo may incr. vilazodone levels, risk of adverse effects (hepatic metabolism inhibited)

  • vorasidenib
  • Multaq (dronedarone)
    +
    vorasidenib
    1 interaction

    Caution Advised

    dronedarone + vorasidenib

    caution advised: combo may decr. dronedarone levels, efficacy (hepatic metabolism possibly induced)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@1623cc56
  • CHF, new or exacerbation
  • QT prolongation
  • torsades de pointes
  • bradycardia
  • hepatotoxicity
  • acute renal failure
  • interstitial lung disease
  • hypersensitivity reaction
  • anaphylaxis
  • photosensitivity

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@28bd1997
  • Cr elevated
  • QT prolongation
  • diarrhea
  • asthenia
  • nausea
  • pruritus
  • rash
  • abdominal pain
  • bradycardia
  • vomiting
  • dyspepsia

Safety/Monitoring .

Monitoring Parameters
pregnancy test at baseline; electrolytes including Mg at baseline, then periodically; BUN/Cr; ECG q3mo; consider LFTs, especially during 1st 6mo of tx

Pregnancy/Lactation .

Pregnancy

Clinical Summary

avoid use during pregnancy; no human data available; risk of teratogenicity based on animal data at 0.5x and 1x MRHD

Individuals of Reproductive Potential

avoid pregnancy by using effective contraception during tx and x5 days after D/C in patients of childbearing potential

Lactation

Clinical Summary

avoid breastfeeding during tx and x5 days after D/C; no human data available to assess risk of infant harm or effects on milk production

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@600844b2

Metabolism: for dronedarone: liver; CYP450: 3A substrate

Excretion: for dronedarone: urine 6%, feces 84%; Half-life: 13-19h

Subclass: Antiarrhythmics, Oral

Mechanism of Action
for dronedarone: exact mechanism of action unknown; exhibits antiarrhythmic properties of all four Vaughn-Williams classes

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: sanofi-aventis U.S. LLC

com.epocrates.rxweb.beans.DrugOtherInfoBean@787b27ac

DEA/FDA: Rx

Retail Price

Estimated prices only. For current pricing, visit GoodRx.

oral tablet:

  • 400 mg (60 ea): $715.00

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information